UNITED STATES
SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

---

Form 10-Q

---

|ý                                             | Quarterly report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 
|--------------------------------------------- | ----------------------------------------------------------------------------------------
|For the quarterly period ended March 31, 2008
|or                                           
|o                                             | Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Commission file number: 1-32203

---

Prospect Medical Holdings, Inc.(Exact name of registrant as specified in its charter)

|Delaware(State or other jurisdiction of incorporation or organization)                              |  | 33-0564370(I.R.S. Employer Identification No.)
|--------------------------------------------------------------------------------------------------- |  | ----------------------------------------------
|10780 Santa Monica Blvd., Suite 400
Los Angeles, California(Address of principal executive offices) |  | 90025(Zip Code)                               
|(310) 943-4500(Registrant's telephone number, including area code)                                 

---

Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the
preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past
90 days. Yes o    No ý

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of
"accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer o

Accelerated filer o

Non-accelerated filer ý


Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act): Yes o    No ý

The number of shares of the issuer's Common Stock, par value $0.01 per share, outstanding as of June 9, 2008 was 11,782,567.



---





PROSPECT MEDICAL HOLDINGS, INC.        Index        Part IFinancial Information

|Item 1.    |  | Financial Statements                                                                                                                |  |   
|---------- |  | ----------------------------------------------------------------------------------------------------------------------------------- |  | --
|           |  | Condensed Consolidated Balance Sheets as of March 31, 2008 (unaudited) and September 30, 2007                                       |  | 3 
|           |  | Condensed Consolidated Statements of Operations for the three-month and six-month periods ended March 31, 2008 and 2007 (unaudited) |  | 5 
|           |  | Condensed Consolidated Statements of Cash Flows for the six-month periods ended March 31, 2008 and 2007 (unaudited)                 |  | 6 
|           |  | Notes to Condensed Consolidated Financial Statements (unaudited)                                                                    |  | 7 
|Item 2.    |  | Management's Discussion and Analysis of Financial Condition and Results of Operations                                               |  | 29
|Item 3.    |  | Quantitative and Qualitative Disclosures About Market Risk                                                                          |  | 53
|Item 4.    |  | Controls and Procedures                                                                                                             |  | 53
|           |  | Part IIOther Information                                                                                                           |  |   
|Item 1.    |  | Legal Proceedings                                                                                                                   |  | 57
|Item 1A.   |  | Risk Factors                                                                                                                        |  | 57
|Item 2.    |  | Unregistered Sales of Equity Securities and Use of Proceeds                                                                         |  | 57
|Item 3.    |  | Defaults Upon Senior Securities                                                                                                     |  | 57
|Item 4.    |  | Submission of Matters to a Vote of Security Holders                                                                                 |  | 59
|Item 5.    |  | Other information                                                                                                                   |  | 59
|Item 6.    |  | Exhibits                                                                                                                            |  | 59
|Signatures |  | 61                                                                                                                                 

2

---





PART IFINANCIAL INFORMATION

Item 1.    Financial Statements.

PROSPECT MEDICAL HOLDINGS, INC.        CONDENSED CONSOLIDATED BALANCE SHEETS

|                                          |                                                                                                                                           | March 31,
2008 |             | September 30, 2007 |  
|----------------------------------------- | ----------------------------------------------------------------------------------------------------------------------------------------- | -------------- | ----------- | ------------------ | -
|
|ASSETS                                    |                                                                                                                                           |                |             |                    |  
|Current assets:                           |                                                                                                                                           |                |             |                    |  
|                                          | Cash and cash equivalents                                                                                                                 |                | $           | 23,638,717         |  
|                                          | Investments, primarily restricted certificates of deposit                                                                                 |                |             | 636,592            |  
|                                          | Patient accounts receivable, net of allowance for doubtful accounts of $4,510,000 and $4,447,000 at March 31, 2008 and September 30, 2007 |                |             | 19,430,942         |  
|                                          | Government program receivables                                                                                                            |                |             | 2,478,248          |  
|                                          | Risk pool receivables                                                                                                                     |                |             | 184,514            |  
|                                          | Other receivables, net of allowances of $763,000 and $632,000 at March 31, 2008 and September 30, 2007                                    |                |             | 3,008,719          |  
|                                          | Notes receivable, current portion                                                                                                         |                |             | 60,424             |  
|                                          | Refundable income taxes                                                                                                                   |                |             | 3,514,080          |  
|                                          | Deferred income taxes, net                                                                                                                |                |             | 3,394,872          |  
|                                          | Prepaid expenses and other                                                                                                                |                |             | 4,980,715          |  
|                                          |                                                                                                                                           |                |             |                    |  
|Total current assets                      |                                                                                                                                           |                | 61,327,823  |                    |  
|Property, improvements and equipment:     |                                                                                                                                           |                |             |                    |  
|                                          | Land and land improvements                                                                                                                |                |             | 18,498,720         |  
|                                          | Buildings                                                                                                                                 |                |             | 22,353,209         |  
|                                          | Leasehold improvements                                                                                                                    |                |             | 2,202,745          |  
|                                          | Equipment                                                                                                                                 |                |             | 10,436,519         |  
|                                          | Furniture and fixtures                                                                                                                    |                |             | 1,004,445          |  
|                                          |                                                                                                                                           |                |             |                    |  
|                                          |                                                                                                                                           |                | 54,495,638  |                    |  
|                                          | Less accumulated depreciation and amortization                                                                                            |                |             | (6,815,122         | )
|                                          |                                                                                                                                           |                |             |                    |  
|Property, improvements and equipment, net |                                                                                                                                           |                | 47,680,516  |                    |  
|Notes receivable, long term portion       |                                                                                                                                           |                | 415,269     |                    |  
|Deposits and other assets                 |                                                                                                                                           |                | 1,067,487   |                    |  
|Deferred financing costs                  |                                                                                                                                           |                | 6,323,381   |                    |  
|Goodwill                                  |                                                                                                                                           |                | 129,116,945 |                    |  
|Other intangible assets, net              |                                                                                                                                           |                | 49,864,445  |                    |  
|                                          |                                                                                                                                           |                |             |                    |  
|Total assets                              |                                                                                                                                           | $              | 295,795,866 |                    | $
|                                          |                                                                                                                                           |                |             |                    |  

See
accompanying notes.

3

---





PROSPECT MEDICAL HOLDINGS, INC.        CONDENSED CONSOLIDATED BALANCE SHEETS        (continued)

|                                           |                                                                                                                                                               | March 31,
2008 |             | September 30, 2007 |  
|------------------------------------------ | ------------------------------------------------------------------------------------------------------------------------------------------------------------- | -------------- | ----------- | ------------------ | -
|
|LIABILITIES AND SHAREHOLDERS' EQUITY       |                                                                                                                                                               |                |             |                    |  
|Current liabilities:                       |                                                                                                                                                               |                |             |                    |  
|                                           | Accrued medical claims and other health care costs payable                                                                                                    |                | $           | 23,226,379         |  
|                                           | Accounts payable and other accrued liabilities                                                                                                                |                |             | 12,234,579         |  
|                                           | Third-party settlements                                                                                                                                       |                |             | 939,403            |  
|                                           | Accrued salaries, wages and benefits                                                                                                                          |                |             | 8,080,548          |  
|                                           | Current portion of capital leases                                                                                                                             |                |             | 334,470            |  
|                                           | Current portion of long-term debt                                                                                                                             |                |             | 10,750,000         |  
|                                           | Other current liabilities                                                                                                                                     |                |             | 5,623,574          |  
|                                           |                                                                                                                                                               |                |             |                    |  
|Total current liabilities                  |                                                                                                                                                               |                | 61,188,953  |                    |  
|Long-term debt, less current portion       |                                                                                                                                                               |                | 136,250,000 |                    |  
|Deferred income taxes                      |                                                                                                                                                               |                | 24,022,260  |                    |  
|Malpractice reserve                        |                                                                                                                                                               |                | 664,375     |                    |  
|Capital leases, net of current portion     |                                                                                                                                                               |                | 628,614     |                    |  
|Interest rate swap liability               |                                                                                                                                                               |                | 10,716,417  |                    |  
|Other long-term liabilities                |                                                                                                                                                               |                | 231,368     |                    |  
|                                           |                                                                                                                                                               |                |             |                    |  
|Total liabilities                          |                                                                                                                                                               |                | 233,701,987 |                    |  
|Minority interest                          |                                                                                                                                                               |                | 87,983      |                    |  
|Shareholders' equity:                      |                                                                                                                                                               |                |             |                    |  
|                                           | Preferred stock, $.01 par value 5,000,000 shares authorized, 1,672,880 issued and outstanding at March 31, 2008 and September 30, 2007                        |                |             | 16,728             |  
|                                           | Common stock, $0.01 par value; 40,000,000 shares authorized; 11,782,567 and 11,402,567 shares issued and outstanding at March 31, 2008 and September 30, 2007 |                |             | 117,826            |  
|                                           | Additional paid-in capital                                                                                                                                    |                |             | 87,140,198         |  
|                                           | Accumulated other comprehensive loss                                                                                                                          |                |             | (5,408,877         | )
|                                           | Accumulated deficit                                                                                                                                           |                |             | (19,859,979        | )
|                                           |                                                                                                                                                               |                |             |                    |  
|Total shareholders' equity                 |                                                                                                                                                               |                | 62,005,896  |                    |  
|                                           |                                                                                                                                                               |                |             |                    |  
|Total liabilities and shareholders' equity |                                                                                                                                                               | $              | 295,795,866 |                    | $
|                                           |                                                                                                                                                               |                |             |                    |  

See
accompanying notes.

4

---





PROSPECT MEDICAL HOLDINGS, INC.        CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS        (Unaudited)

|                                                                          |                                                               | Three months ended
March 31, |            | Six months ended
March 31, |  
|------------------------------------------------------------------------- | ------------------------------------------------------------- | ---------------------------- | ---------- | -------------------------- | -
|
|Revenues:                                                                 |                                                               |                              |            |                            |  
|                                                                          | Managed care revenues                                         |                              | $          | 54,946,620                 |  
|                                                                          | Net patient revenues                                          |                              |            | 32,396,126                 |  
|                                                                          |                                                               |                              |            |                            |  
|Total revenues                                                            |                                                               |                              | 87,342,746 |                            |  
|Operating expenses:                                                       |                                                               |                              |            |                            |  
|                                                                          | Managed care cost of revenues                                 |                              |            | 42,830,455                 |  
|                                                                          | Hospital operating expenses                                   |                              |            | 20,966,977                 |  
|                                                                          | General and administrative                                    |                              |            | 15,936,555                 |  
|                                                                          | Depreciation and amortization                                 |                              |            | 1,918,542                  |  
|                                                                          |                                                               |                              |            |                            |  
|Total operating expenses                                                  |                                                               |                              | 81,652,529 |                            |  
|Operating income from unconsolidated joint venture                        |                                                               |                              | 694,218    |                            |  
|                                                                          |                                                               |                              |            |                            |  
|Operating income (loss)                                                   |                                                               |                              | 6,384,435  |                            |  
|Other income (expense):                                                   |                                                               |                              |            |                            |  
|                                                                          | Investment income                                             |                              |            | 149,068                    |  
|                                                                          | Interest expense and amortization of deferred financing costs |                              |            | (5,382,991                 | )
|                                                                          | Loss on interest rate swap                                    |                              |            |                           |  
|                                                                          |                                                               |                              |            |                            |  
|Total other income (expense), net                                         |                                                               |                              | (5,233,923 | )                          |  
|                                                                          |                                                               |                              |            |                            |  
|Income (loss) before income taxes                                         |                                                               |                              | 1,150,512  |                            |  
|Provision (benefit) for income taxes                                      |                                                               |                              | 419,525    |                            |  
|                                                                          |                                                               |                              |            |                            |  
|Net income (loss) before minority interest                                |                                                               |                              | 730,987    |                            |  
|Minority interest                                                         |                                                               |                              | 3,000      |                            |  
|                                                                          |                                                               |                              |            |                            |  
|Net income (loss) before preferred dividend                               |                                                               |                              | 727,987    |                            |  
|Dividends to preferred stockholders                                       |                                                               |                              | (1,982,999 | )                          |  
|                                                                          |                                                               |                              |            |                            |  
|Net loss attributable to common
stockholders                              |                                                               | $                            | (1,255,012 | )                          | $
|                                                                          |                                                               |                              |            |                            |  
|Per share data:                                                           |                                                               |                              |            |                            |  
|Net loss per share attributable to common stockholdershistorical:        |                                                               |                              |            |                            |  
|                                                                          | Basic                                                         |                              | $          | (0.11                      | )
|                                                                          |                                                               |                              |            |                            |  
|                                                                          | Diluted                                                       |                              | $          | (0.11                      | )
|                                                                          |                                                               |                              |            |                            |  
|Net income (loss) per share attributable to common stockholdersproforma: |                                                               |                              |            |                            |  
|                                                                          | Basic                                                         |                              | $          | 0.04                       |  
|                                                                          |                                                               |                              |            |                            |  
|                                                                          | Diluted                                                       |                              | $          | 0.04                       |  
|                                                                          |                                                               |                              |            |                            |  

See
accompanying notes.

5

---





PROSPECT MEDICAL HOLDINGS, INC.        CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS        (Unaudited)

|                                   |                                                                                                    | Six months ended
March 31,                                                              |                                                           
|---------------------------------- | -------------------------------------------------------------------------------------------------- | --------------------------------------------------------------------------------------- | ----------------------------------------------------------
|
|Operating activities               |                                                                                                    |                                                                                         |                                                           
|                                   | Net income (loss)                                                                                  |                                                                                         | $                                                         
|                                   | Adjustments to reconcile net income (loss) to net cash provided by (used in) operating activities: |                                                                                         |                                                           
|                                   |                                                                                                    | Depreciation and amortization                                                           |                                                           
|                                   |                                                                                                    | Amortization of deferred financing costs                                                |                                                           
|                                   |                                                                                                    | Provision for bad debts                                                                 |                                                           
|                                   |                                                                                                    | Stock based compensation                                                                |                                                           
|                                   |                                                                                                    | Deferred income taxes, net                                                              |                                                           
|                                   |                                                                                                    | Loss on interest rate swaps                                                             |                                                           
|                                   |                                                                                                    | Changes in assets and liabilities:                                                      |                                                           
|                                   |                                                                                                    |                                                                                         | Risk pool receivables                                     
|                                   |                                                                                                    |                                                                                         | Patient and other receivables                             
|                                   |                                                                                                    |                                                                                         | Prepaid expenses and other                                
|                                   |                                                                                                    |                                                                                         | Refundable income taxes                                   
|                                   |                                                                                                    |                                                                                         | Deposits and other assets                                 
|                                   |                                                                                                    |                                                                                         | Accrued medical claims and other health care costs payable
|                                   |                                                                                                    |                                                                                         | Accounts payable and other accrued liabilities            
|                                   |                                                                                                    |                                                                                         |                                                           
|                                   | Net cash provided by (used in) operating activities                                                |                                                                                         |                                                           
|Investing activities               |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Purchases of property, improvements and equipment                                       |                                                           
|                                   |                                                                                                    | Collections on notes receivable                                                         |                                                           
|                                   |                                                                                                    | Decrease in restricted certificates of deposit                                          |                                                           
|                                   |                                                                                                    | Capitalized expenses related to acquisitions                                            |                                                           
|                                   |                                                                                                    | Other investing activities                                                              |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Net cash used in investing activities                                                   |                                                           
|Financing activities               |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Borrowings on line of credit                                                            |                                                           
|                                   |                                                                                                    | Repayments on line of credit                                                            |                                                           
|                                   |                                                                                                    | Repayments of long term debt                                                            |                                                           
|                                   |                                                                                                    | Payments on capital leases                                                              |                                                           
|                                   |                                                                                                    | Proceeds from exercises of stock options and warrants                                   |                                                           
|                                   |                                                                                                    | Excess benefits from options exercised                                                  |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Net cash provided by (used in) financing activities                                     |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Net increase (decrease) in cash and cash equivalents                                    |                                                           
|                                   |                                                                                                    | Cash and cash equivalents at beginning of period                                        |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Cash and cash equivalents at end of period                                              |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           
|Supplemental cash flow information |                                                                                                    |                                                                                         |                                                           
|                                   | Non-cash investing and financing activities:                                                       |                                                                                         |                                                           
|                                   |                                                                                                    | Dividend on preferred shares                                                            |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Equipment acquired under capital lease                                                  |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           
|                                   |                                                                                                    | Change in interest rate swap liability recorded as other comprehensive loss, net of tax |                                                           
|                                   |                                                                                                    |                                                                                         |                                                           

6

---





PROSPECT MEDICAL HOLDINGS, INC.        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS        March 31, 2008        (Unaudited)

1. Business

Prospect Medical Holdings, Inc. ("Prospect", or the "Company") is a Delaware corporation. Prior to the August 8, 2007 acquisition of Alta Healthcare
System, Inc. ("Alta"), the Company was primarily engaged in providing management services to affiliated physician organizations that operate as independent physician associations ("IPAs") or
medical clinics. With the acquisition of Alta, the Company now owns and operates four community-based hospitals in Southern California and its operations are now organized into two reportable
segments, IPA Management and Hospital Services, as discussed below.

As
further discussed in Note 7, the operating results for the three-month and six-month periods ended March 31, 2008 include the ProMed Entities acquired on
June 1, 2007 and Alta acquired on August 8, 2007.

Liquidity and Recent Operating Results

The Company recorded a non-cash impairment charge of approximately $38.8 million in the fourth quarter of 2007 to write off goodwill and
intangibles within the IPA Management segment, which resulted in losses in the Company's core operations during fiscal 2007, although operating activities have generated positive cash flows from 2005
to 2007. The improvement of the Company's core operations and the successful integration of its newly acquired subsidiaries have required and will continue to require significant investment and
management attention. The Company is undertaking a review of its operations to improve profitability and efficiency and to reduce costs, which may include the divestiture of non-strategic
assets.

The
Company is subject to certain financial and administrative covenants, cross default provisions and other conditions required by the loan agreements with the lenders, including a
maximum senior debt/EBITDA (earnings before interest, taxes, depreciation and amortization) ratio and a minimum fixed-charge coverage ratio, each computed quarterly based on consolidated trailing
twelve-month operating results, including the pre-acquisition operating results of any acquired entities. The administrative covenants and other restrictions with which the Company must
comply include, among others, restrictions on additional indebtedness, incurrence of liens, engaging in business other than the Company's primary business, paying certain dividends, acquisitions and
asset sales. The credit facility provides that an event of default will occur if there is a change in control.

While
the Company has met all debt service requirements timely, it did not comply with certain financial and administrative convents as of September 30, 2007 and for periods
thereafter as discussed in Note 6. The Company did not make timely filings of its Form 10-K for the year ended September 30, 2007 and its Forms 10-Q
for the quarters ended December 31, 2007 and March 31, 2008. Effective January 16, 2008, trading of the Company's shares was suspended. The Company filed its
Form 10-K on June 2, 2008 and its Form 10-Q for the quarter ended December 31, 2007 on June 9, 2008.

On
February 13, 2008, April 10, 2008 and May 14, 2008, the Company and its lenders entered into forbearance agreements, whereby the lenders agreed not to exercise
their rights under the credit facility through May 15, 2008, subject to satisfaction of specified conditions. On May 15, 2008, the Company and its lenders entered into an agreement to
waive past covenant violations and to amend the financial

7

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

1. Business (Continued)

covenant
provisions prospectively. Effective May 15, 2008, the maximum senior debt/EBITDA ratios were increased to levels ranging from 3.90 to 7.15 for monthly reporting periods from
April 30, 2008 through June 30, 2009 and were increased to levels ranging from 3.30 to 3.75 beginning with the September 30, 2009 quarterly reporting period through maturity of
the term loan. The minimum fixed charge coverage ratios were reduced to levels ranging from 0.475 to 0.925 for monthly reporting periods from April 30, 2008 through June 30, 2009 and
were reduced to levels ranging from 0.85 to 0.90 beginning with the September 30, 2009 quarterly reporting period through maturity of the term loan. The Company is also required to meet a
minimum EBITDA for future monthly reporting periods from April 30, 2008 through June 30, 2009 and the remaining quarterly periods through maturity of the term loan. In addition, the
Company is required to, among other conditions, file its Form 10-K for the year ended September 30, 2007 and Forms 10-Q for the quarters ended
December 31, 2007 and March 31, 2008 by June 16, 2008. Failure to perform any obligation under the waiver and the amended credit facility agreement constitutes an additional event
of default. As noted above, the Company filed its Form 10-K on June 2, 2008 and its Form 10-Q for the quarter ended December 31, 2007 on
June 9, 2008.

As
discussed in Note 6, for the period January 28, 2008 through April 10, 2008, interest was assessed at default interest rates. Under the April 2008 forbearance
agreement, the applicable margin on the first and second lien term loans and the revolver were permanently increased effective April 10, 2008. During the forbearance periods, the Company had
limited or no access to the line of credit. The Company also agreed to pay certain fees and expenses to the lenders.

Management
has implemented a turnaround plan to improve the operating results of the IPA Management segment, including measures to retain and increase enrollment, increase health plan
reimbursements and reduce medical costs. Proceeds from any future sale of non-strategic assets will be used to reduce debt service. Management believes that it will be able to comply with
all covenants, as modified, at least through the next twelve months, including filing its Form 10-Q for the quarter ended March 31, 2008 by June 16, 2008, and timely
filing of its Form 10-Q for the quarter ended June 30, 2008 and its Form 10-K for the year ended September 30, 2008 and has included scheduled
payments
due after twelve months from the balance sheet date as non-current liabilities at September 30, 2007 and March 31, 2008.

However,
there can be no assurance that this turnaround plan will have a successful outcome and that the Company will be able to meet all of the financial covenants and other conditions
required by the loan agreements for future periods. The lenders may not provide forbearance or grant waivers of future covenant violations and could require full and immediate repayment of the loans,
which would negatively impact the Company's liquidity, ability to operate and ability to continue as a going concern.

IPA Management

The IPA Management segment is a health care management services organization that develops integrated delivery systems, and provides medical management systems
and services to affiliated medical organizations. The affiliated medical organizations employ and/or contract with physicians and professional medical corporations, and contract with managed care
payors. Prospect currently manages

8

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

1. Business (Continued)

the
provision of prepaid health care services for its affiliated medical organizations in Southern California.

Hospital Services

Alta Healthcare System, Inc. ("Alta"), acquired on August 8, 2007, is a wholly-owned subsidiary of Prospect Medical Holdings, Inc. Alta owns
and operates (i) Alta Hollywood Hospitals, Inc., a California corporation, dba Hollywood Community Hospital and Van Nuys Community Hospital; and (ii) Alta Los Angeles
Hospitals, Inc., a California corporation dba Los Angeles Community Hospital and Norwalk Community Hospital. Alta and its subsidiaries (collectively, the Hospital Services segment) own and
operate four hospitals in the greater Los Angeles area with a combined 339 licensed beds served by 351 on-staff physicians. Each of the three hospitals in Hollywood, Los Angeles and
Norwalk offers a comprehensive range of medical and surgical services, including inpatient, outpatient, skilled nursing and urgent care services. The hospital in Van Nuys provides acute inpatient and
outpatient psychiatric services on a voluntary basis. Admitting physicians are primarily practitioners in the local area. The hospitals have payment arrangements with Medicare, Medi-Cal
and other third-party payers, including commercial insurance carriers, health maintenance organizations ("HMOs") and preferred provider organizations ("PPOs").

2. Significant Accounting Policies

Basis of Presentation

The unaudited condensed consolidated interim financial statements have been prepared under the assumption that users of the interim financial data have either
read or have access to our audited consolidated financial statements for the latest fiscal year ended September 30, 2007. Accordingly, certain note disclosures that would substantially
duplicate the disclosures contained in the September 30, 2007 audited financial statements have been omitted. These unaudited condensed consolidated interim financial statements should be read
in conjunction with our September 30, 2007 audited financial statements.

The
unaudited condensed consolidated financial statements include the accounts of the Company and all majority owned subsidiaries and controlled entities under Emerging Issues Task Force
("EITF") No. 97-2, "Application of FASB Statement No. 94 and APB Opinion No. 16 to Physician Practice Management Entities and Certain Other
Entities with Contractual Management Arrangements"and Financial Accounting Standards Board ("FASB") Interpretation No. 46, "Consolidation of
Variable Interest Entities, an Interpretation of ARB No. 51" ("FIN 46"). In the opinion of management, all adjustments considered necessary for a fair
presentation of the results as of the date of, and for the interim periods presented, which consist solely of normal recurring adjustments, have been included. All significant inter-company balances
and transactions have been eliminated in consolidation. The consolidated results of operations for the current interim period are not necessarily indicative of the results that may be expected for the
entire year ending September 30, 2008.

9

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

2. Significant Accounting Policies (Continued)

Revenues and Cost Recognition

Revenues by reportable segments are comprised of the following amounts:

|                     |                             | Three Months Ended
March 31, |            | Six Months Ended
March 31,
|-------------------- | --------------------------- | ---------------------------- | ---------- | --------------------------
|
|IPA Management(1)    |                             |                              |            |                           
|                     | Capitation                  |                              | $          | 54,133,965                
|                     | Fee for service             |                              |            | 582,864                   
|                     | Management fees             |                              |            | 146,767                   
|                     | Other                       |                              |            | 83,024                    
|                     |                             |                              |            |                           
|                     | Total managed care revenues |                              | $          | 54,946,620                
|                     |                             |                              |            |                           
|Hospital Services(2) |                             |                              |            |                           
|                     | Inpatient                   |                              | $          | 30,159,537                
|                     | Outpatient                  |                              |            | 1,860,356                 
|                     | Other                       |                              |            | 376,233                   
|                     |                             |                              |            |                           
|                     | Total net patient revenues  |                              | $          | 32,396,126                
|                     |                             |                              |            |                           
|Total revenues       |                             | $                            | 87,342,746 |                           
|                     |                             |                              |            |                           

---

The
Company presents segment information externally the same way management uses financial data internally to make operating decisions and assess performance. With the acquisition of
Alta Healthcare System, Inc. in August 2007, the Company's operations are now organized into two reporting segments: (i) IPA Management, and (ii) Hospital Services.

10

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

2. Significant Accounting Policies (Continued)

Comprehensive Income (Loss)

Comprehensive income (loss) includes net income (loss) and changes in the fair value of interest rate swaps subject to hedge accounting that are recorded as other
comprehensive income. The components of comprehensive loss for the periods ended March 31 are as follows:

|                                                          |  | Three months ended
March 31, |            | Six months ended
March 31, |  
|--------------------------------------------------------- |  | ---------------------------- | ---------- | -------------------------- | -
|
|Net income (loss)                                         |  | $                            | 727,987    |                            | $
|Change in fair value of interest rate swaps, net of taxes |  |                              | (2,951,145 | )                          |  
|                                                          |  |                              |            |                            |  
|Comprehensive loss                                        |  | $                            | (2,223,157 | )                          | $
|                                                          |  |                              |            |                            |  

3. Stock Based Compensation

The Company has stock option agreements with certain directors, officers and employees. Under Statement of Financial Accounting Standards (SFAS)
No. 123(R), "Share-Based Payments," compensation cost for all share-based payments in exchange for employee services (including stock options and
restricted stock) is measured at fair value on the date of grant estimated using an option pricing model.

Compensation
costs for stock based awards are measured and recognized in the financial statements, net of estimated forfeitures over the awards' requisite service period. The Company
uses the Black-Scholes option pricing model and a single option award approach to estimate the fair value of options granted. Equity-based compensation is classified within the same line items as cash
compensation paid to employees. Cash retained as a result of excess tax benefits relating to share-based payments are presented in the statement of cash flows as a financing cash inflow.

The
stock options generally vest pro-rata over 2 years (the requisite service period) and expire after 5 years from the date of grant. There are no awards with
performance or market vesting conditions. Estimated forfeitures will be revised in future periods if actual forfeitures differ from the estimates and will impact compensation cost in the period in
which the change in estimate occurs. The determination of fair value using the Black-Scholes option-pricing model is affected by the Company's stock price as well as assumptions regarding a number of
complex and subjective variables, including expected stock price volatility, risk-free interest rate, expected dividends and projected employee stock option exercise behaviors.

11

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

3. Stock Based Compensation (Continued)

Option
activity for the six months ended March 31, 2008 is summarized below:

Shares

Weighted Average Exercise Price

Aggregate Intrinsic Value

Weighted Average Remaining Contractual Terms (Months)Outstanding as of September 30, 2007

2,249,906

$
4.57

$


Granted









Exercised

(380,000
)






Forfeited

(39,020
)






Outstanding as of March 31, 2008

1,830,886

$
4.83

$


22Vested and exercisable as of March 31, 2008

1,754,129

$
4.82

$


20


The
aggregate intrinsic value is calculated as the difference between the exercise price of the underlying awards and the quoted price of our common stock for those awards that have an
exercise price currently below the quoted value. As discussed in Note 1, due to untimely filing of its Form 10-K for the year ended December 31, 2007 and its
Forms 10-Q for the quarters ended December 31, 2007 and March 31, 2008, trading of the Company's shares was suspended effective January 16, 2008. As such, the
aggregate intrinsic value of the outstanding and the vested and exercisable stock options at March 31, 2008, could not be determined.

No
stock options were granted during the six months ended March 31, 2008. During the six-months ended March 31, 2007, the Company granted 120,000 fully vested
options to its outside directors at an exercise price of $5.81 per share and recognized expense of $355,200. During the six months ended March 31, 2008, options for 380,000 common shares were
exercised for net proceeds of $1,200,000 and 39,020 options were forfeited. The aggregate intrinsic value of the options exercised was $741,700. During the six months ended March 31, 2007,
options for 495,917 common shares were exercised for cash and on a cashless basis for net proceeds of $940,223 and 46,932 options were forfeited. The aggregate intrinsic value of the options exercised
was approximately $1,292,000. No net tax benefits were realized from the fiscal 2008 exercises of stock options as the Company was in a net taxable loss position in the first quarter of fiscal 2008.
The Company realized net tax benefits of $229,368 in the six months ended March 31, 2007, from those exercises where the price paid was below the fair value of the common shares on the exercise
date. The tax benefits reduced income tax payable and increased additional paid-in capital. At March 31, 2008, there were 76,757 unvested options and compensation of $134,780 for
the unvested options will be recognized ratably over the remaining two year vesting period. At March 31, 2007, there were no unvested awards and no unrecognized stock-based compensation costs.

In
January 2007, warrants for 484,545 common shares were exercised for cash and on a cashless basis for net proceeds of $786,162 and warrants for 14,564 common shares were forfeited.

12

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

4. Earnings Per Share

We follow SFAS No. 128, "Earnings per Share," which established standards regarding the computation of
basic and diluted earnings per share ("EPS"). Net income is reduced by preferred stock dividends to determine earnings attributable to common stockholders for the period. Basic net income per share is
then calculated by dividing income attributable to common stockholders by the weighted average number of common shares outstanding.

The
calculations of basic and diluted net income per share for the three months and six months ended March 31, 2008 and 2007 are as follows:

|         |                                                                                                           | Three months ended
March 31, |            | Six months ended
March 31, |  
|-------- | --------------------------------------------------------------------------------------------------------- | ---------------------------- | ---------- | -------------------------- | -
|
|Basic:   |                                                                                                           |                              |            |                            |  
|         | Net loss attributable to common stockholders                                                              |                              | $          | (1,255,012                 | )
|         |                                                                                                           |                              |            |                            |  
|         | Weighted average number of common shares outstanding                                                      |                              |            | 11,782,567                 |  
|         |                                                                                                           |                              |            |                            |  
|         | Basic net loss earnings per share attributable to common stockholders                                     |                              | $          | (0.11                      | )
|         |                                                                                                           |                              |            |                            |  
|Diluted: |                                                                                                           |                              |            |                            |  
|         | Net loss attributable to common stockholders                                                              |                              | $          | (1,255,012                 | )
|         |                                                                                                           |                              |            |                            |  
|         | Weighted average number of common shares outstanding                                                      |                              |            | 11,782,567                 |  
|         | Weighted average number of dilutive common equivalents from options and warrants to purchase common stock |                              |            |                           |  
|         |                                                                                                           |                              |            |                            |  
|         |                                                                                                           |                              | 11,782,567 |                            |  
|         |                                                                                                           |                              |            |                            |  
|         | Diluted loss earnings per common share                                                                    |                              | $          | (0.11                      | )
|         |                                                                                                           |                              |            |                            |  

The
number of options and warrants excluded from the computation of diluted earnings per share in the three-month and six-month periods ended March 31, 2008, were
1,830,886, and 1,016,536, respectively, prior to the application of the treasury stock method, due to their antidilutive effect. Options and warrants excluded from diluted earnings per share in the
three-month and six-month periods ended March 31, 2007 were 2,389,398 and 1,016,536, respectively. 1,672,880 preferred shares have also been excluded from diluted earnings per share
in the 2008 periods, since their conversion is contingent upon shareholder approval and would have been anti-dilutive.

The
preferred shares are entitled to accrue dividends at 18% per year compounded annually. However, all accrued dividends will be canceled upon conversion of the preferred shares into
common shares upon approval by the Company's shareholders as is expected at the next scheduled shareholders' meeting.

13

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

4. Earnings Per Share (Continued)

The
following proforma basic and diluted earnings per share assumes the conversion of preferred shares into common stock at a ratio of 1:5 at the beginning of the first quarter of fiscal
2008:

|                                                                          |                                                                                                                     | Three Months Ended March 31, 2008 |      | Six Months Ended March 31, 2008 |  
|------------------------------------------------------------------------- | ------------------------------------------------------------------------------------------------------------------- | --------------------------------- | ---- | ------------------------------- | -
|Basic:                                                                    |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Net loss attributable to common stockholdershistorical                                                             |                                   | $    | (1,255,012                      | )
|                                                                          | Add dividend to preferred stockholders                                                                              |                                   |      | 1,982,999                       |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Net income attributable to common stockholdersproforma                                                             |                                   | $    | 727,987                         |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Weighted average number of common shares outstandinghistorical                                                     |                                   |      | 11,782,567                      |  
|                                                                          | Add number of preferred shares converted to common shares                                                           |                                   |      | 8,364,400                       |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Weighted average number of common shares outstandingproforma                                                       |                                   |      | 20,146,967                      |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|Basic net income per share attributable to common stockholdersproforma   |                                                                                                                     | $                                 | 0.04 |                                 | $
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|Diluted:                                                                  |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Net loss attributable to common stockholdershistorical                                                             |                                   | $    | (1,255,012                      | )
|                                                                          | Add dividend to preferred stockholders                                                                              |                                   |      | 1,982,999                       |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Net income attributable to common stockholdersproforma                                                             |                                   | $    | 727,987                         |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Weighted average number of common shares outstandinghistorical                                                     |                                   |      | 11,782,567                      |  
|                                                                          | Add number of preferred shares converted to common shares                                                           |                                   |      | 8,364,400                       |  
|                                                                          | Add weighted average number of dilutive common equivalent shares from options and warrants to purchase common stock |                                   |      | *                              |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|                                                                          | Weighted average number of dilutive common shares outstandingproforma                                              |                                   |      | 20,146,967                      |  
|                                                                          |                                                                                                                     |                                   |      |                                 |  
|Diluted net income per share attributable to common stockholdersproforma |                                                                                                                     | $                                 | 0.04 |                                 | $
|                                                                          |                                                                                                                     |                                   |      |                                 |  

*  No
effect has been given to the dilutive common equivalent shares from options and warrants since the Company's common stock suspended trading on January 16, 2008
and the weighted average share price cannot be determined for the periods presented.

5. Related Party Transactions

Prospect Medical Holdings, Inc. has a controlling financial interest in the affiliated physician organizations included in its consolidated financial
statements which are owned by a nominee physician shareholder designated by the Company. The control is effectuated through assignable option agreements and management services agreements, which
provide the Company a unilateral right to

14

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

5. Related Party Transactions (Continued)

establish
or effect a change of the nominee shareholder for the affiliated physician organizations at will, and without the consent of the nominee, on an unlimited basis and at nominal cost through
the term of the management agreement. Jacob Y. Terner, M.D. is currently the sole shareholder, sole director and Chief Executive Officer of Prospect Medical Group and is the Chief Executive Officer of
each of Prospect's subsidiary physician organizations, except for AMVI/Prospect and Nuestra. Dr. Terner is also a shareholder of the Company, and formerly served as its Chairman and Chief
Executive Officer.

The
Company had an employment agreement with Dr. Terner that expires August 1, 2008 and provides for base compensation ($400,000 per year) and further provides that if the
Company terminates Dr. Terner's employment without cause, the Company will be required to pay him $12,500 for each month of past service as the Chief Executive Officer, commencing as of
July 31, 1996, up to $1,237,500. Dr. Terner resigned as the Chief Executive Officer effective March 19, 2008 and resigned as the chairman of the board of directors effective
May 12, 2008. In consideration for Dr. Terner's resignation as chairman of the board and other promises in his resignation agreement, and in satisfaction of our contractual obligations
under Dr. Terner's employment agreement, we agreed to pay to his family trust the sum of $19,361.10 each month during the twelve-month period ending on April 30, 2009 and the sum of
$42,694.45 each month during the twenty-four month period ending on April 30, 2011, for the total sum of $1,257,000. A charge will be recorded in the third quarter of 2008 for the
present value of the payments payable to Dr. Terner's family trust.

Dr. Terner
has agreed to continue to serve temporarily as the sole shareholder, sole director and Chief Executive Officer of Prospect Medical Group and its subsidiary physician
organizations until a suitable replacement can be found.

Through
the ProMed acquisition, the Company acquired the lease of an office facility which is owned by a shareholder of the Company, who formerly was an executive officer and shareholder
of ProMed.
The total lease payments in the six months ended March 31, 2008 under this lease were approximately $232,000.

6. Long Term Debt

Long-term debt at March 31, 2008 and September 30, 2007, respectively, consists of the following:

March 31,
2008

September 30, 2007Term loan

$
141,250,000

$
143,750,000Revolving credit facility, interest at prime rate plus applicable margin


5,750,000


3,000,000$
147,000,000

$
146,750,000Less current maturities


(10,750,000
)

(8,000,000
)$
136,250,000

$
138,750,000


On
September 27, 2004, the Company entered into a senior secured credit facility with Residential Funding Corporation ("RFC," a subsidiary of General Motors Acceptance
Corporation) that consisted

15

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

6. Long Term Debt (Continued)

of
a $10,000,000 term loan and a $5,000,000 revolving credit facility. Amounts outstanding under the term loan bore interest at a rate of prime plus 2% per annum and amounts outstanding under the
revolving credit facility bore interest at a rate of prime plus 0.5% per annum.

In
November 2005, in connection with an acquisition of an IPA, RFC provided the Company with an additional $4 million term loan on terms similar to the existing term loan.

All
amounts owing to RFC ($7,842,000, plus $209,000 of prepayment penalties) were repaid on June 1, 2007, from proceeds of a new three-year senior secured credit
facility entered into with Bank of America, in connection with the purchase of the ProMed Entities (see Note 7). The Bank of America facility totaled $53,000,000, and comprised a $48,000,000
variable-rate term loan, and a $5,000,000 revolver (which had not been drawn). The $48,000,000 term loan was repaid on August 8, 2007, with proceeds from a new $155,000,000
syndicated senior secured credit facility arranged by Bank of America in connection with the acquisition of Alta, comprising a $95,000,000, seven year first-lien term loan at LIBOR plus
400 basis points (8.70% at March 31, 2008), with quarterly payments of $1,250,000 and an annual principal payment of 50% of excess cash flow, as defined in the loan agreement; a $50,000,000
seven and one-half year second-lien term loan at LIBOR plus 825 basis points (12.95% at March 31, 2008), with all principal due at maturity and a revolving credit
facility of $10,000,000 which bears interest at prime plus a margin that ranges from 275 to 300 basis points based on the consolidated leverage ratio (10.25% at March 31, 2008). The Company may
borrow, make repayments and re-borrow under the revolver until August 8, 2012, at which time all outstanding amounts must be repaid. $3 million was drawn on the revolving
line of credit at closing with an additional $2.75 million in the first and second quarters of 2008, which remained outstanding at March 31, 2008.

The
Company recorded an interest charge of $895,914 to write off deferred financing costs upon the extinguishment of the $53 million credit facility and capitalized approximately
$6.9 million in deferred financing costs on the $155 million credit facility in August 2007, which will be amortized over the term of the related debt using the effective interest
method.

As
required by the $53 million credit facility, on May 16, 2007, the Company entered into a $48 million interest rate swap, which effectively converts the variable
interest rate (the LIBOR component) under the credit facility to a fixed rate of 5.3%, plus the applicable margin per year throughout the term of the loan. This interest rate swap remains in effect
even though the related term loan was repaid in August 2007.

In
addition to the pre-existing $48,000,000 interest rate swap described above, on September 5, 2007, the Company entered into a separate interest rate swap agreement
for the incremental debt, initially totaling $97,750,000 which effectively converts the variable interest rate (the LIBOR component) under the incremental portion of the $155 million credit
facility to a fixed rate of 5.05%, plus the applicable margin, per year, throughout the term of the loan. The notional amounts of these interest rate swaps are scheduled to decline as the principal
balances owing under the term loans decline. Under these swaps, the Company is required to make quarterly fixed-rate payments to the counterparties calculated on the notional amount of the
swap and the interest rate for the particular swap, while the counterparties are obligated to make certain monthly floating rate payments to the Company referencing the same notional amount. These
interest rate swaps effectively fix the weighted

16

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

6. Long Term Debt (Continued)

average
annual interest rate payable on the term loans to 5.13%, plus the applicable margin. Notwithstanding the terms of the interest rate swap transactions, the Company is ultimately obligated for
all amounts due and payable under its existing credit facility.

The
interest rate swap agreements are designated as cash flow hedges of expected interest payments on long term debt with the effective date of the $48,000,000 swap being
December 31, 2007 and the effective date of the $97,750,000 swap being September 6, 2007. Prior to the hedge effective dates, all mark-to-market adjustments in
the value of the swaps are charged to other expense. Total gains or losses on all cash flow swaps charged to earnings for the six-month period ended March 31, 2008 were
approximately $877,000. After the hedge effective date, the effective portions of the fair value gains or losses on these cash flow hedges are initially recorded as a component of other comprehensive
income and subsequently reclassified into earnings when the forecasted transaction affects earnings. The cumulative loss recorded in other comprehensive income at March 31, 2008 that is
expected to be reclassified to interest expense in the future is approximately $5,409,000, after tax. There were no components of cash flow hedges that were excluded from the assessment of
effectiveness.

The
Company is subject to certain financial and administrative covenants, cross default provisions and other conditions required by the loan agreements with the lenders, including a
maximum senior debt/EBITDA ratio and a minimum fixed-charge coverage ratio, each computed quarterly based on consolidated trailing twelve-month results, including the pre-acquisition
results of any acquired entities. The administrative covenants and other restrictions with which the Company must comply include, among others, restrictions on additional indebtedness, incurrence of
liens, engaging in business other than the Company's primary business, paying certain dividends, acquisitions and asset sales. The credit facility provides that an event of default will occur if there
is a change in control. The payment of principal and interest under the credit facility is fully and unconditionally guaranteed, jointly and severally by the Company and most of its existing
wholly-owned subsidiaries. Substantially, all of the Company's assets are pledged to secure the credit facility. The Company exceeded the maximum senior debt/EBITDA ratio of 3.75 as of
September 30, 2007, December 31, 2007 and March 31, 2008. The Company also failed to meet the minimum fixed charge coverage ratio of 1.25 as of and for the trailing twelve-month
periods ended December 31, 2007 and March 31, 2008. In addition, the Company did not comply with certain administrative covenants including timely filing of its
Form 10-K for the year ended September 30, 2007 and its Forms 10-Q for the quarters ended December 31, 2007 and March 31, 2008. The Company
filed its
Form 10-K on June 2, 2008 and its Form 10-Q for the quarter ended December 31, 2007 on June 9, 2008.

On
February 13, 2008, April 10, 2008 and May 14, 2008, the Company and its lenders entered into forbearance agreements, whereby the lenders agreed not to exercise
their rights under the credit facility through May 15, 2008, subject to satisfaction of specified conditions. For the period January 28, 2008 through April 10, 2008, interest was
assessed at default rates of 11.4% with respect to the first lien term loan and 15.4% with respect to the second-lien term loan. Under the April 2008 forbearance agreements, the applicable
margin on the first and second lien term loans were permanently increased to 750 and 1,175 basis points, respectively, and the range of applicable margins on the revolving line of credit was increased
to 500 to 750 basis points effective April 10, 2008. During the forbearance periods,

17

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

6. Long Term Debt (Continued)

the
Company had limited or no access to the line of credit. The Company also agreed to pay certain fees and expenses to the lenders and their advisors as described below.

On
May 15, 2008, the Company and its lenders entered into an agreement to waive past covenant violations and amended the financial covenant provisions prospectively starting in
April 2008 to modify the required ratios and to increase the frequency of compliance reporting from quarterly to monthly for a specified period. Effective May 15, 2008, the maximum senior
debt/EBITDA ratios were increased to levels ranging from 3.90 to 7.15 for future monthly reporting periods from April 30, 2008 through June 30, 2009 and were increased to levels ranging
from 3.30 to 3.75 beginning with the September 30, 2009 quarterly reporting period through maturity of the term loan. The minimum fixed charge coverage ratios were reduced to levels ranging
from 0.475 to 0.925 for monthly reporting periods from April 30, 2008 through June 30, 2009 and were reduced to levels ranging from 0.85 to 0.90 beginning with the September 30,
2009 quarterly reporting period through maturity of the term loan. The Company is also required to meet a new minimum EBITDA requirement for future monthly reporting periods from April 30, 2008
through June 30, 2009 and the remaining quarterly reporting periods through maturity of the term loan. In addition, the Company is required to, among other conditions, file its
Form 10-K for the year ended September 30, 2007 and the Forms 10-Q for the quarters ended December 31, 2007 and March 31, 2008 by
June 16, 2008. Failure to perform any obligations under the waiver and the amended credit facility agreement constitutes additional events of default. As noted above, the Company filed its
Form 10-K on June 2, 2008 and its Form 10-Q for the quarter ended December 31, 2007 on June 9, 2008. The Company has met all debt service
requirements on a timely basis.

The
Company believes that it will be able to comply with the adjusted financial ratios at least for the next twelve months. As such, scheduled payments due after twelve months have been
classified as non-current at September 30, 2007 and March 31, 2008. However, there can be no assurance that the Company will be able to meet all of the financial covenants
and other conditions required by the loan agreements for periods beyond twelve months. The lenders may not provide forbearance or grant waivers of future covenant violations and could require full
repayment of the loans, which would negatively impact the Company's liquidity, ability to operate and its ability to continue as a going concern.

In
connection with obtaining the waivers and amendments, the Company was required to pay $675,000 in fees to Bank of America, $2,274,000 in forbearance fees to the lenders, $400,000 in
legal and consulting fees to the lenders' advisors, and add 1% to the principal balance of the first and second lien debt of $1,415,000. In addition, the Company will incur an additional 4%
"payment-in-kind" interest expense on the second lien debt, which accrues and is added to the principal balance. The 4% may be reduced on a quarterly basis by 0.50% for each
0.25% reduction in the Company's consolidated leverage ratio. Interest expense for the quarter ended March 31, 2008 includes interest at the default rates referenced above and $762,500 paid to
the lenders under the forbearance agreements. The Company also incurred $610,931 in fees to the lenders and their advisors related to the forbearance agreements, which was included in general and
administrative expenses. In addition, under the amended senior credit facility agreement, all net proceeds from any future sale of one or more of the Company's IPAs are to be used to prepay the
outstanding balance of the first lien debt (see Note 12).

18

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

7. Acquisition

ProMed Entities

On June 1, 2007, the Company and its affiliated physician organization, Prospect Medical Group, Inc. ("PMG") completed the acquisition of ProMed
Health Services Company, a California corporation and its subsidiary, ProMed Health Care Administrators, Inc. (collectively referred to as "ProMed Health Care Administrators"), and two
affiliated IPAs; Pomona Valley Medical Group, Inc., dba ProMed Health Network ("Pomona Valley Medical Group"), and Upland Medical Group, Inc. ("Upland Medical Group"), (collectively
referred to as the "ProMed Entities"). ProMed Health Care Administrators ("PHCA") manages the medical care of HMO enrollees served by Pomona Valley Medical Group and Upland Medical Group. Total
purchase consideration of $48,000,000 included $41,040,000 of cash and 1,543,237 shares of Prospect Medical common stock valued at $6,960,000, or $4.51 per share. The transaction is referred to as the
"ProMed Acquisition."

The
ProMed Acquisition, and $372,000 in related transaction costs, was financed by $48,000,000 in borrowings (less $896,000 in debt issuance costs) and $2,359,000 from cash reserves. The
debt proceeds and cash reserves were used to fund the cash consideration of $41,040,000 and to repay all existing debt of Prospect Medical ($7,842,000 plus $209,000 of prepayment penalties). The
$48,000,000 in borrowings used to finance the acquisition of the ProMed Entities was refinanced in August 2007, using proceeds from the $155,000,000 credit facility entered into in connection with the
Alta transaction, described below. The purchase agreements provide for certain post-closing working capital and medical claims reserve adjustments. Any final settlement payments made to,
or received from, the sellers of the ProMed Entities, when finally determined, will be reported as an adjustment to goodwill. Such adjustments cannot be reasonably estimated at this time.

Alta Healthcare System, Inc.

On August 8, 2007, the Company acquired the outstanding common shares of Alta Healthcare System, Inc., a California corporation ("Alta") and the
name of the surviving entity was changed to Alta Hospitals System, LLC. The purchase transaction is referred to as the "Alta Acquisition." Alta is a private, for-profit hospital
management company that, through two subsidiary corporations, owns and operates four community-based hospitalsVan Nuys Community Hospital, Hollywood Community Hospital, Los Angeles
Community Hospital and Norwalk Community Hospital. These hospitals provide a comprehensive range of medical, surgical and psychiatric services and have a combined 340 licensed beds served by 351
on-staff physicians. Total purchase consideration, including transaction costs, was approximately $154,895,000, including repayment of approximately $41,500,000 of Alta's existing debt,
payment of approximately $51,300,000 in cash to the former Alta shareholders, issuance of 1,887,136 shares of Prospect common stock, issuance of 1,672,880 shares of Prospect convertible preferred
stock valued, for purposes of the transaction, at $61,030,000, and payment of transaction costs of $1,117,714. Each share of preferred stock will automatically convert into five common shares upon
approval by a shareholders vote that was scheduled for November 2007 but was postponed and is anticipated to be convened in mid (calendar) 2008. Until conversion occurs, each share of preferred stock
accrues dividends at 18% per year, compounding annually. However, no dividends will be paid upon conversion to common shares. For purposes of determining the number of shares to be issued in
connection with the transaction, Prospect common stock was valued at $5.00 per share and Prospect preferred stock was

19

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

7. Acquisition (Continued)

valued
at $25.00 per share. However, for purposes of recording the transaction, (i) the value per share of common stock was estimated at $5.58, based on the average of the stock's closing
prices before and after the acquisition announcement date of July 25, 2007, and (ii) the value per share of preferred stock was estimated at $30.19, based on the closing stock price of
common share on the acquisition date plus a premium for the preference features of the stock. As such, total recorded purchase consideration, exclusive of transaction costs, was $153,772,000. At
March 31, 2008, accrued dividends of $4,987,308 were included in other current liabilities. Upon conversion of the preferred shares into common shares at the next scheduled shareholders'
meeting, the accrued dividends are expected to be forgiven and the liability will be reclassified to additional paid-in capital.

The
Alta Acquisition, the extinguishment of Alta's existing debt and the refinancing of the ProMed Acquisition debt described above were financed by a $155,000,000 senior secured credit
facility arranged by Bank of America, comprising $145,000,000 in term loans and a $10,000,000 revolver, of which $3,000,000 was drawn at closing. The term debt is comprised of a $95,000,000, seven
year first-lien term loan at LIBOR plus 400 basis points, with quarterly principal payments of $1,250,000 and an annual principal payment of 50% of excess cash flow, as defined in the loan
agreement; and a $50,000,000 seven and one-half year second-lien term loan, at LIBOR plus 825 basis points, with all principal due at maturity (see Note 6 for discussion
of long-term debt). Net proceeds of $141.1 million (net of issuance discount and financing costs of $6.9 million) were used to repay Alta's existing borrowings of
$41.5 million, refinance $47.0 million in outstanding ProMed acquisition debt, pay the cash portion of the purchase price of $51.3 million and fund $1.1 million in direct
transaction costs.

20

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

7. Acquisition (Continued)

The
following table summarizes the estimated fair values of the assets acquired and liabilities assumed, as of the date of acquisition, and cash paid for the ProMed Entities and Alta.

The
allocation of the purchase price for the ProMed and Alta acquisitions is as follows:

ProMed

AltaAcquisition costsCash consideration

$
41,040,000

$
51,257,675Stock consideration


6,960,000


61,030,284Debt assumption and repayments





41,484,650Direct acquisition costs


372,330


1,117,714Aggregate purchase consideration

$
48,372,330

$
154,890,323Allocation of purchase priceNet tangible assets

$
3,622,143

$
54,001,536Amortizable intangibles:Customer relationships

$
25,200,000

$
Trade names


9,450,000


14,140,000Covenants not-to-compete


940,000


2,240,000Provider networks


1,200,000


Total amortizable intangible assets

$
36,790,000

$
16,380,000Net deferred tax liabilities on book-tax basis difference in assets acquired


(14,663,043
)

(21,984,928
)Goodwill


22,623,230


106,493,715$
48,372,330

$
154,890,323Net cash paidAggregate purchase consideration

$
48,372,330

$
154,890,323Stock consideration


(6,960,000
)

(61,030,284
)Cash acquired


(5,331,339
)

(376,182
)Net cash paid in acquisition

$
36,080,991

$
93,483,857


21

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

7. Acquisition (Continued)

The
following table represents the acquired companies' summarized balance sheet at the date of acquisition:

ProMed

AltaCash

$
5,331,339

$
376,182Other current assets


5,890,305


26,052,818Property and equipment


375,972


46,804,000Other noncurrent assets


77,459


Accounts payable and current liabilities


(8,052,932
)

(17,902,876
)Other noncurrent liabilities acquired





(1,328,588
)Tangible net assets

$
3,622,143

$
54,001,536


Goodwill
from the ProMed and Alta Acquisitions are primarily related to a new platform for future growth, driven by new geographic markets and business segments, as well as an
experienced management team and workforce. Through the ProMed Acquisition, the Company expanded into a new service market in the Pomona Valley and Inland Empire areas. With the Alta Acquisition, the
Company purchased a hospital network and now operates as an integrated healthcare delivery system with in-network medical groups and acute care facilities. As a stock purchase, the
goodwill and a significant portion of the intangible assets acquired in the ProMed and Alta Acquisitions are not deductible for income tax purposes. Future tax liabilities related to the fair value of
these assets in excess of the tax deductible amounts have been recorded as deferred tax liabilities on the acquisition date.

The
following unaudited pro forma financial information for the three-month and six-month periods ended March 31, 2007 gives effect to the acquisition of ProMed and
Alta as if they had occurred on October 1, 2006. Such unaudited pro forma information is based on historical financial information with respect to the acquisition and does not include
synergies, operational or other changes that might have been effected by the Company.

Significant
proforma adjustments include increase in interest expense related to the acquisition debt, increased depreciation and amortization related to fixed assets and amortizable
intangibles acquired, adjustment to income taxes for acquired entities that previously operated as S-corporations, reduction in interest income to reflect cash consideration paid and
distributions by acquired entities to selling shareholders, the elimination of intercompany management fees among the ProMed Entities and

22

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

7. Acquisition (Continued)

increased
common shares outstanding to reflect shares issued in the acquisitions including the preferred shares on an as-converted basis.

|                             |         | Three months ended
March 31,
2007 |            | Six months ended
March 31,
2007
|---------------------------- | ------- | --------------------------------- | ---------- | -------------------------------
|
|Net revenue                  |         | $                                 | 81,294,614 |                                
|Net income (loss)            |         | $                                 | (3,650,398 | )                              
|Net income (loss) per share: |         |                                   |            |                                
|                             | Basic   |                                   | $          | (0.19                          
|                             |         |                                   |            |                                
|                             | Diluted |                                   | $          | (0.19                          
|                             |         |                                   |            |                                

No
effect has been given to the preferred stock dividends as the pro forma calculations assume the immediate conversion of preferred shares into common stock at the acquisition date.

8. Segment Information

Statement of Financial Accounting Standards No. 131, "Disclosures about Segments of an Enterprise and Related Information," provides disclosure guidelines
for segments of a company based on a management approach to defining reporting segments.

With
the acquisition of Alta in August 2007, the Company's operations are now organized into two reporting segments: (i) IPA Managementwhich is comprised of the
Prospect and ProMed operating units, provides management services to affiliated physician organizations that operate as IPAs or medical clinics; and (ii) Hospital Serviceswhich
owns and operates four community-based hospitalsLos Angeles Community Hospital, Hollywood Community Hospital, Norwalk Community Hospital and Van Nuys Community Hospital.

The
accounting policies of the reporting segments are the same as those described elsewhere in this Form 10-Q and in the summary of significant accounting policies in
Note 2 to the consolidated financial statements in the Form 10-K for the year ended September 30, 2007. The Company evaluates financial performance and allocates
resources primarily based on earnings from continuing operations before interest expense, interest income, income taxes, depreciation and amortization, as well as earnings from operations before
income taxes, excluding infrequent or unusual items.

23

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

8. Segment Information (Continued)

The
reporting segments are strategic business units that offer different services within the healthcare continuum. Business in each reporting segment is conducted by one or more direct
or indirect wholly-owned subsidiaries of the Company. Each of these subsidiaries has separate governing bodies.

The
following tables summarize certain information for each of the reporting segments regularly provided to and reviewed by the chief operating decision maker as of and for the
three-month and six-month periods ended March 31, 2008:

As of and for the Three Months Ended March 31, 2008IPA Management(1)

Hospital Services

Intersegment Eliminations

ConsolidatedRevenues from external customers

$
54,946,620

$
32,396,126

$


$
87,342,746Intersegment revenues











Total revenues


54,946,620


32,396,126





87,342,746Operating income (loss)


(1,426,726
)

7,811,161





6,384,435Investment income


149,068








149,068Interest expense


(5,341,713
)

(41,278
)




(5,382,991
)Income (loss) before income taxes

$
(6,619,371
)
$
7,769,883

$


$
1,150,512Identifiable segment assets

$
241,765,016

$
74,676,002

$
(20,645,152
)
$
295,795,866Segment capital expenditures

$
106,871

$
386,613

$


$
493,484Segment goodwill

$
22,623,230

$
106,493,715

$


$
129,116,945


|
|

As of and for the Six Months Ended March 31, 2008IPA Management(1)

Hospital Services

Intersegment Eliminations

ConsolidatedRevenues from external customers

$
109,921,005

$
59,682,354

$


$
169,603,359Intersegment revenues











Total revenues


109,921,005


59,682,354





169,603,359Operating income (loss)


(3,257,761
)

13,746,980





10,489,219Investment income


443,192








443,192Interest expense


(9,599,255
)

(79,823
)




(9,679,078
)Loss on interest rate swaps


(876,680
)







(876,680
)Income (loss) before income taxes

$
(13,290,504
)
$
13,667,157

$


$
376,653Identifiable segment assets

$
241,765,016

$
74,676,002

$
(20,645,152
)
$
295,795,866Segment capital expenditures

$
240,619

$
850,918

$


$
1,091,537Segment goodwill

$
22,623,230

$
106,493,715

$


$
129,116,945




24

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

8. Segment Information (Continued)



9. Use of Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions
that affect the reported amounts of assets, liabilities, revenues and expenses, and the disclosure of contingent assets and liabilities at the dates and for the periods that the financial statements
are prepared. Actual results could differ from those estimates. Principal areas requiring the use of estimates include third-party cost report settlements, risk-sharing programs, patient
and medical related receivables, determination of allowances for contractual discounts and uncollectible accounts, medical claims and accruals, impairment of goodwill, long-lived and
intangible assets, valuation of interest rate swaps, share-based payments, professional and general liability claims, reserves for the outcome of litigation, liabilities for uncertain income tax
positions and valuation allowances for deferred tax assets.

During
the six months ended March 31, 2008 and 2007, we recorded approximately $2,202,000 and $336,000, respectively, in reduced claims expense related to favorable development of
fiscal 2007 and 2006 claims.

10. New Accounting Pronouncements

On July 13, 2006, the FASB issued Interpretation No. 48, "Accounting For Uncertainty in Income TaxesAn
Interpretation of FASB Statement No. 109" ("FIN 48"). FIN 48 clarifies the accounting for uncertainty in income taxes recognized in an entity's financial
statements in accordance with FASB Statement No. 109, "Accounting for Income Taxes," and prescribes a recognition threshold and measurement
attributes for financial statement disclosure of tax positions taken or expected to be taken on a tax return. Under FIN 48, the impact of an uncertain income tax position on the income tax
return must be recognized at the largest amount that is more-likely-than-not to be sustained upon audit by the relevant taxing authority. An uncertain income tax
position will not be recognized if it has less than a 50% likelihood of being sustained. Additionally, FIN 48 provides guidance on derecognition,

25

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

10. New Accounting Pronouncements (Continued)

classification,
interest and penalties, accounting in interim periods, disclosure and transition. FIN 48 is effective for fiscal years beginning after December 15, 2006.

The
Company adopted the provisions of FIN 48 on October 1, 2007. There are no unrecognized tax benefits as of the date of adoption. As a result of the implementation of
FIN 48, the Company recognized no decrease in deferred tax assets or changes in the valuation allowance. There is no unrecognized tax benefits included in the balance sheet that would, if
recognized, affect the effective tax rate.

The
Company's practice is to recognize interest and/or penalties related to income tax matters in income tax expense. Upon adoption of FIN 48 on October 1, 2007, the
Company did not record any interest or penalties.

Consolidated
and separate income tax returns are filed with the U.S. Federal jurisdiction and in the State of California. The Company's filed tax returns are subject to examination by
both the IRS and the State of California for fiscal years 2004, 2005 and 2006.

The
adoption of FIN 48 did not impact the Company's consolidated financial condition, results of operations or cash flows. At March 31, 2008, the Company had net deferred
tax liabilities of
$20.6 million. The net deferred tax liabilities are primarily composed of temporary differences between book and tax balances for intangible and capital assets acquired, losses on interest rate
swaps and some loss carryforwards.

In
September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" ("SFAS No. 157.") This Statement defines fair
value, establishes a framework for measuring fair value in generally accepted accounting principles, and expands disclosures about fair value measurements. This Statement applies under other
accounting pronouncements that require or permit fair value measurements, the Board having previously concluded in those accounting pronouncements that fair value is the relevant measurement
attribute. Accordingly, this Statement does not require any new fair value measurements. This Statement is effective for financial statements issued for fiscal years beginning after
November 15, 2007, and interim periods within those fiscal years. The Company is required to adopt the provisions of SFAS No. 157 on October 1, 2008, and is currently evaluating
the impact of the provision of SFAS No. 157.

In
February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for Financial Assets and Financial LiabilitiesIncluding an Amendment of
FASB Statement No. 115," ("SFAS No. 159"). SFAS No. 159 permits a company to choose to measure many financial instruments and certain other items at fair
value at specified election dates. Most of the provisions in SFAS No. 159 are elective; however, it applies to all companies with available-for-sale and trading
securities. A company will report unrealized gains and losses on items for which the fair value option has been elected in earnings at each subsequent reporting date. The fair value option:
(a) may be applied instrument by instrument, with a few exceptions, such as investments otherwise accounted for by the equity method; (b) is irrevocable (unless a new election date
occurs), and; (c) is applied only to entire instruments and not to portions of instruments. SFAS No. 159 is effective as of the beginning of a company's first fiscal year beginning after
November 15, 2007. The Company will adopt SFAS No. 159 on October 1, 2008 and is currently

26

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

10. New Accounting Pronouncements (Continued)

evaluating
this statement. Management has not yet determined if it will elect to measure any additional financial assets and liabilities at fair value.

In
December 2007, the FASB issued SFAS No. 141 (revised 2007) "Business Combinations"("SFAS No. 141(R)"). SFAS
No. 141(R) establishes new principles and requirements for how the acquirer of a business recognizes and measures in its financial statements the identifiable assets acquired, the liabilities
assumed, and any noncontrolling interest in the acquiree. SFAS No. 141(R) also provides guidance for recognizing and measuring the goodwill acquired in the business combination and determines
what information to disclose to enable users of the financial statements to evaluate the nature and financial effects of the business combination. In general, SFAS No. 141(R) requires the
acquiring entity to recognize all the assets acquired and liabilities assumed in the transaction and establishes the acquisition-date fair value as the measurement objective. This standard
will, among other things, impact the determination of acquisition-date fair value of consideration paid in a business combination, including recognition of contingent consideration and
most pre-acquisition loss and gain contingencies at their acquisition-date fair values. It will also require companies to expense as incurred transaction costs, and recognize
changes in income tax valuation allowances and tax uncertainty accruals that result from a business
combination as adjustments to income tax expense. SFAS 141(R) will also place new restrictions on the ability to capitalize acquisition-related restructuring costs. SFAS No. 141(R)
applies prospectively to business combinations in the first annual reporting period beginning on or after December 15, 2008. The Company will adopt SFAS No. 141(R) on October 1,
2009. Management is currently evaluating the potential impact of the adoption of SFAS No. 141(R) on its consolidated financial statements.

In
December 2007, the FASB issued SFAS 160, "Noncontrolling Interests in Consolidated Financial Statementsan Amendment of ARB
No. 51"("SFAS No. 160"). SFAS No. 160 establishes accounting and reporting standards for the noncontrolling interest in a subsidiary and for the
deconsolidation of a subsidiary. It clarifies that a noncontrolling (minority) interest in a subsidiary is an ownership interest in the consolidated entity that should be reported as equity in the
consolidated financial statements separate from parent's equity. Net income attributable to the non controlling interest will be included in consolidated net income on the face of the income
statement. SFAS No. 160 is effective for fiscal years, and interim periods within those fiscal years, beginning on or after December 15, 2008. SFAS No. 160 requires retroactive
adoption of the presentation and expanded disclosure requirements for existing minority interests. All other requirements of SFAS No. 160 shall be applied prospectively. The Company will adopt
SFAS No. 160 on October 1, 2009 and is currently evaluating the potential impact of the adoption of SFAS No. 160 on its consolidated financial statements.

11. Litigation and Contingencies

Many of the Company's payor and provider contracts are complex in nature and may be subject to differing interpretations regarding amounts due for the provision
of medical services. Such differing interpretations may not come to light until a substantial period of time has passed following contract implementation. Liabilities for claims disputes are recorded
when the loss is probable and can be estimated. Any adjustments to reserves are reflected in current operations.

27

---



PROSPECT MEDICAL HOLDINGS, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (Continued)

March 31, 2008

(Unaudited)

11. Litigation and Contingencies (Continued)

The
Company is subject to a variety of claims and suits that arise from time to time in the ordinary course of its business. While management currently believes that resolving all of
these matters, individually or in the aggregate, will not have a material adverse impact on the Company's financial
position or its results of operations, the litigation and other claims that the Company faces are subject to inherent uncertainties and management's view of these matters may change in the future.
Should an unfavorable final outcome occur, there exists the possibility of a materially adverse impact on the Company's financial position, results of operations and cash flows for the period in which
the effect becomes probable and reasonably estimable.

12. Subsequent Event

On April 23, 2008, the Company entered into a Stock Purchase Agreement ("SPA"), pursuant to which the Company agreed to sell, subject to buyer's due
diligence, all of the issued and outstanding stock of certain of its IPAs for $10 million. Pursuant to the SPA, the Company provided the requested due diligence and schedules on May 21,
2008. The buyer stated that they would not proceed with the transaction unless they received additional time to complete their diligence review. Consequently, the parties are currently in the process
of further discussions relating to due diligence, and other possible issues. As discussed in Note 6, pursuant to the amended senior credit facility agreement, all net proceeds from the possible
sale are to be used to prepay the outstanding balance of the first lien debt.

On
May 15, 2008, the Company and its lenders entered into an agreement to waive past covenant violations and amended the financial covenant provisions prospectively starting in
April 2008 to (i) modify the required ratios and (ii) increase the frequency of compliance reporting.

28

---





Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations.

Forward-Looking Statements

The following discussion of our financial condition and results of operations should be read in conjunction with the accompanying unaudited condensed consolidated
financial statements and the notes to those statements appearing elsewhere in this report and the audited financial statements for the year ended September 30, 2006 appearing in our annual
report on Form 10-K filed with the Securities and Exchange Commission.

This
discussion contains forward-looking statements that involve risks and uncertainties. These forward-looking statements are often accompanied by words such as "believe," "should,"
"anticipate," "plan," "expect," "potential," "scheduled," "estimate," "intend," "seek," "goal," "may" and similar expressions. These statements include, without limitation, statements about our market
opportunity, our growth strategy, competition, expected activities and future acquisitions and investments and the adequacy of our available cash resources. Investors are urged to read these
statements carefully, and are cautioned that matters subject to forward-looking statements involve risks and uncertainties, including economic, regulatory, competitive and other factors that may
affect our business. These statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions. Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, we do not assume any responsibility for the accuracy and
completeness of such statements in the future. Subject to applicable law, we do not plan to update any of the forward-looking statements after the date of this report to conform such statements to
actual results.

Forward-looking
statements involve known and unknown risks and uncertainties that may cause our actual results in future periods to differ materially from those projected or contemplated
in the forward-looking statements as a result of, but not limited to, the following factors:



29

---





30

---





31

---





Investors
should also refer to our Form 10-K annual report filed on June 2, 2008, and our Form 10-Q quarterly report filed on June 9,
2008 for a discussion of risk factors. Given these risks and uncertainties, we can give no assurances that results projected in any forward-looking statements will in fact occur and therefore caution
investors not to place undue reliance on them.

Overview

Prior to the August 8, 2007 acquisition of Alta, the Company has been primarily a health care management services organization that develops integrated
delivery systems and provides medical management systems and services to affiliated medical organizations. With the acquisition of Alta, the Company now owns and operates four community-based
hospitals in Southern California and its operations are now organized into two primary reportable segments.

IPA Management

The IPA Management segment is a health care management services organization that provides management services to affiliated physician organizations that operate
as independent physician associations ("IPAs") or medical clinics. The affiliated physician organizations enter into agreements with health maintenance organizations ("HMOs") to provide enrollees of
the HMOs with a full range of medical services in exchange for fixed, prepaid monthly fees known as "capitation" payments. The IPAs contract with physicians (primary care and specialist) and other
health care providers to provide all of their medical services. The medical clinics employ their primary care physicians, which provide the vast majority of their medical services, while contracting
with specialist physicians and other health care providers to provide other required medical services.

Through
our management subsidiariesProspect Medical Systems, Sierra Medical Management and ProMed Health Care Administratorswe have entered into
long-term agreements to provide management services to each of our affiliated physician organizations in exchange for a management fee. The management services we provide include HMO
contracting, physician recruiting, credentialing and contracting, human resources services, claims administration, financial services, provider relations, patient eligibility and other services,
medical management including utilization management and quality assurance, data collection, and management information systems.

Our
management subsidiaries currently provide management services to fifteen affiliated physician organizations, which include Prospect Medical Group, thirteen other affiliated physician
organizations that Prospect Medical Group owns or controls, and one affiliated physician organization (AMVI/Prospect Health Network) that is an unconsolidated joint venture in which Prospect Medical
Group owns a 50% interest. We have utilized Prospect Medical Group, which was our first affiliated physician organization, to acquire the ownership interest in all of our other affiliated physician
organizations.

32

---



Thus,
while Prospect Medical Group is itself an affiliated physician organization that does the same business in its own service area as all of our other affiliated physician organizations do in
theirs, Prospect Medical Group also serves as a holding company for our other affiliated physician organizations.

The
fifteen affiliated physician organizations provide medical services to a combined total of approximately 228,000 HMO enrollees at March 31, 2008, including approximately 8,700
AMVI Prospect Health Network enrollees that we manage for the economic benefit of an independent third party, and for which we earn management fee income.

Currently,
our affiliated physician organizations have contracts with approximately twenty HMOs, from which our revenue is primarily derived. HMOs offer a comprehensive health care
benefits package in exchange for a capitation fee per enrollee that does not vary through the contract period regardless of the quantity or cost of medical services required or used. HMOs enroll
members by entering into contracts with employer groups or directly with individuals to provide a broad range of health care services for a prepaid charge, with minimal deductibles or
co-payments required of the members. All of the contracts between our affiliated physician organizations and the HMOs provide for the provision of medical services by the affiliated
physician organization to the HMO enrollees in consideration for the prepayment of the fixed monthly capitation fee per enrollee.

Our
IPA Management business has grown through the acquisition of IPAs by Prospect Medical Group. Our plan is for Prospect Medical Group to selectively continue to acquire IPAs. We do not
intend to further acquire any individual or small medical practices, clinics or medical group practices.

We
have chosen to concentrate our growth geographically by limiting our acquisitions to IPAs in Orange County, California, Los Angeles County, California and San Bernardino County,
California.

Managed
care revenues consist primarily of fees for medical services provided by our affiliated physician organizations under capitated contracts with various HMOs or under
fee-for-service arrangements. Capitation revenue under HMO contracts is prepaid monthly to the affiliates based on the number of enrollees electing any one of the affiliates as
their health care provider. Capitation revenue may be subsequently adjusted to reflect changes in enrollment as a result of retroactive terminations or additions. These adjustments have not had a
material effect on capitation revenue. Capitation revenue is also subject to risk adjustments. Beginning in calendar 2004, Medicare began a four year phase-in of a revised capitation model
referred to as "Risk Adjustment." Under the new model, capitation with respect to Medicare enrollees is subject to subsequent adjustment for the acuity of the enrollees to whom services were provided.
Capitation for the current year is paid based on data submitted for each enrollee for the preceding year. Capitation is paid at interim rates during the year and is adjusted in subsequent periods
(generally in the fourth quarter) after the final data is compiled. Positive or negative capitation adjustments are made for seniors with conditions requiring more or less healthcare services than
assumed in the interim payments. Since we do not currently have the ability to reliably predict these adjustments, periodic changes in capitation amounts earned as a result of Risk Adjustment are
recognized when those changes are communicated from the health plans, generally in the fourth quarter of the fiscal year to which the adjustments relate. Management fees primarily comprise amounts
earned from managing the operations of AMVI, Inc., which is our joint venture partner in the AMVI/Prospect Health Network joint venture. Management services have historically related only to
Medi-Cal members. However, starting in fiscal 2006, this was expanded to also include management services related to Medicare members enrolling in CalOPTIMA's OneCare HMO, as well as
management services provided to Brotman Medical Center, an equity investee in which we hold a 38% interest. OneCare is a Medicare Advantage Special Needs Plan launched in August 2005 by CalOPTIMA to
serve dually-eligible members in Orange County who are entitled to Medicare benefits and are also Medi-Cal eligible. Management fee revenue is earned in the month the services are
delivered. Managed care revenues include incentive payments from HMOs under

33

---



"pay-for-performance"
programs for quality medical care based on various criteria. These incentives are generally received in the third and fourth quarters of our fiscal year
and are recorded when such amounts are known since we do not have the information to reliably estimate these amounts. Risk pool and pay-for-performance incentives are affected
by many factors, some of which are beyond the Company's control, and may vary significantly from year to year.

We
also earn additional incentive revenue or incur penalties under HMO contracts by sharing in the risk for hospitalization based upon inpatient services utilized. These amounts are
included in capitation revenue. Except for two minor contracts where we are contractually obligated for down-side risk, shared risk deficits are not payable until and unless we generate
future risk sharing surpluses. Risk pools are generally settled in the following year. Management estimates risk pool incentives based on information received from the HMOs or hospitals with whom the
risk-sharing arrangements are in place, and who typically maintain the information and record keeping related to the risk pool arrangements. Differences between actual and estimated
settlements are recorded when the final outcome is known.

Revenues
are comprised of the following amounts:

|                |  | Three months ended
March 31, |            |  |   | Six months ended
March 31, |  |       |   
|--------------- |  | ---------------------------- | ---------- |  | - | -------------------------- |  | ----- | --
|
|
|Capitation      |  | $                            | 54,133,965 |  | $ | 32,455,047                 |  | 66.8  | % 
|Fee for service |  |                              | 582,864    |  |   | 516,999                    |  | 12.7  | % 
|Management fees |  |                              | 146,767    |  |   | 193,102                    |  | (24.0 | )%
|Other           |  |                              | 83,024     |  |   | 161,838                    |  | (48.7 | )%
|                |  |                              |            |  |   |                            |  |       |   
|Total           |  | $                            | 54,946,620 |  | $ | 33,326,986                 |  | 64.9  | % 
|                |  |                              |            |  |   |                            |  |       |   

We
have increased our membership through acquisitions. These increases through acquisition are offset by HMO enrollment declines at our affiliated physician organizations, similar to the
general HMO enrollment trends in California in recent years. The following table sets forth the approximate number of members, by category.

Member Category

As of
March 31,
2008

As of
March 31,
2007

% Increase
(Decrease)Commercialowned

170,500

136,800

24.6
%Commercialmanaged

1,300

1,300

0.0
%Seniorowned

22,800

13,700

66.4
%Seniormanaged

100

100

0.0
%MediCalowned

26,400

11,000

140.0
%MediCalmanaged

7,300

5,900

23.7
%Total

228,400

168,800

35.3
%


34

---



The
following table details total paid member months, by member category, for the three-month and six-month periods ended March 31, 2008 and 2007:

|                   |  | Three months ended
March 31, |  |         |  | Six months ended
March 31, |   |           | 
|------------------ |  | ---------------------------- |  | ------- |  | -------------------------- | - | --------- | 
|
|
|Commercialowned   |  | 514,500                      |  | 415,800 |  | 23.7                       | % | 1,059,100 | 
|Commercialmanaged |  | 4,000                        |  | 3,900   |  | 2.6                        | % | 7,900     | 
|Seniorowned       |  | 69,900                       |  | 41,800  |  | 67.2                       | % | 139,900   | 
|Seniormanaged     |  | 400                          |  | 400     |  | 0.0                        | % | 800       | 
|MediCalowned      |  | 78,400                       |  | 28,100  |  | 179.0                      | % | 154,000   | 
|MediCalmanaged    |  | 21,500                       |  | 17,500  |  | 22.9                       | % | 44,700    | 
|                   |  |                              |  |         |  |                            |   |           | 
|                   |  | 688,800                      |  | 507,500 |  | 35.7                       | % | 1,402,500 | 
|                   |  |                              |  |         |  |                            |   |           | 

Our
operating expenses include expenses related to the provision of medical care services (managed care cost of revenues) and general and administrative, or G&A, costs. Our results of
operations depend on our ability to effectively manage expenses related to health benefits and accurately predict costs incurred.

Expenses
related to medical care services include payments to contracted primary care physicians, payments to contracted specialists and the cost of employed physicians at the Company's
medical clinics. In general, primary care physicians are paid on a capitation basis, while specialists are paid on either a capitation or a fee-for-service basis.

Capitation
payments are fixed in advance of periods covered and are not subject to significant accounting estimates. These payments are expensed in the period the providers are obligated
to provide services. Fee-for-service payments are expensed in the period services are provided to our members. Medical care costs include actual historical claims experience
and estimates of medical expenses incurred but not reported, or IBNR. Monthly, we estimate our IBNR based on a number of factors, including prior claims experience. As part of this review, we also
consider estimates
of amounts to cover uncertainties related to fluctuations in provider billing patterns, claims payment patterns, membership and medical cost trends. These estimates are adjusted monthly as more
information becomes available. In addition to our own IBNR estimation process, we obtain semi-annual certifications of our IBNR liability from independent actuaries. We believe that our
process for estimating IBNR is adequate, but there can be no assurance that medical care costs will not exceed such estimates. In addition to contractual reimbursements to providers, we also make
discretionary incentive payments to physicians, which are in large part based on the pay-for-performance, shared risk revenues and favorable senior capitation risk adjustment
payments we receive. Since the Company records these revenues generally in the third or fourth quarter of each fiscal year, when the incentives and capitation adjustments due from the health plans are
known, the Company also records the discretionary physician bonuses in the same period. Since incentives and risk adjustment revenues form the basis for these discretionary bonuses, variability in
earnings due to fluctuations in revenues are mitigated by reductions in bonuses awarded.

Beginning
with the first quarter of fiscal 2007 and continuing through the quarter ended December 31, 2007, the Company has experienced an increase in fee for service claims costs
per member per month. In December 2007, the Company undertook a turnaround plan to increase health plan reimbursements and reduce medical spending in our core operations by renegotiating payor and
provider contracts, capitalizing certain specialties, strengthening claims adjudication and audit functions, accelerating claims recovery, adopting a new fee schedule for non-contract
claims, and improving medical management. These measures have begun to reduce claims costs in our core operations in the quarter ended March 31, 2008.

G&A
costs are largely comprised of wage and benefit costs related to our employee base and other administrative expenses. G&A functions include claims processing, information systems,
provider relations, finance and accounting services, and legal and regulatory services.

35

---



Hospital Services

The Hospital Services segment owns and operates four urban acute-care community hospitals in the greater Los Angeles area with a combined 339 licensed
beds served by 351 on-staff physicians. Each of the three hospitals in Hollywood, Los Angeles and Norwalk offers a comprehensive range of medical and surgical services, including
inpatient, outpatient, skilled nursing and urgent care services. The hospital in Van Nuys provides acute inpatient and out patient psychiatric services on a voluntary basis. Admitting physicians are
primarily practitioners in the local area. The hospitals have payment arrangements with Medicare, Medi-Cal and other third-party payors including some commercial insurance carriers, Health
Maintenance Organizations ("HMOs") and Preferred Provider Organizations ("PPOs"). The basis for such payments involving inpatient and outpatient services rendered includes prospectively determined
rates per discharge and cost-reimbursed methodologies. The hospitals are also eligible for State of California Disproportionate Share ("DSH") payments based on a prospective payment system
for hospitals that serve large proportions of low-income patients.

Operating
revenue of our Hospital Services segment consists primarily of payments for services rendered, including estimated retroactive adjustments under reimbursement arrangements with
third-party payors. In some cases, reimbursement is based on formulas and reimbursable amounts are not considered final until cost reports are filed and audited or otherwise settled by the various
programs. The Company accrues for amounts that it believes will ultimately be due to or from Medicare and other third-party payors and reports such amounts as net patient revenues in the accompanying
financial statements. We closely monitor our historical collection rates, as well as changes in applicable laws, rules and regulations and contract terms, to assure that provisions are made using the
most accurate information available. However, due to the complexities involved in these estimations, actual payments from payors may be different from the amounts we estimate and record. A summary of
the payment arrangements with major third-party payors follows:

Medicare:
Medicare is a federal program that provides certain hospital and medical insurance benefits to persons aged 65 and over, some disabled persons with end-stage renal
disease and certain other beneficiary categories. Inpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates per discharge, according to a patient
classification system based on clinical, diagnostic, and other factors. Outpatient services are paid based on a blend of prospectively determined rates and cost-reimbursed methodologies.
The Company is also reimbursed for various disproportionate share and Medicare bad debt components at tentative rates, with final settlement determined after submission of annual Medicare cost reports
and audit thereof by the
Medicare fiscal intermediary. Normal estimation differences between final settlements and amounts accrued in previous years are reflected in net patient service revenue in the year of final
settlement.

Medi-Cal:
Medi-Cal is a joint federal-state funded health care benefit program that is administered by the state of California to provide benefits to qualifying
individuals who are unable to afford care. Inpatient services rendered to Medi-Cal program beneficiaries are paid at contracted per diem rates. The per diem rates are not subject to
retrospective adjustment. Outpatient services are paid based on prospectively determined rates per procedure provided.

Managed
Care: The Company also receives payment from certain commercial insurance carriers, HMOs, and PPOs, though generally does not enter into contracts with these entities. The basis
for payment under these agreements includes the Company's standard charges for services.

Self
Pay: Our hospitals provide services to individuals that do not have any form of health care coverage. Such patients are evaluated, at the time of service or shortly thereafter, for
their ability to pay based upon federal and state poverty guidelines, qualifications for Medi-Cal, as well as our local hospital's indigent and charity care policy.

36

---



The
following tables show the approximate percentages of net patient revenue from each major payer category during the three-month and six-month periods ended
March 31, 2008. Net patient revenues are defined as revenues from all sources of patient care after deducting contractual allowances and discounts from established billing rates, which we
derived from various sources of payment for the periods indicated.

Three months ended
March 31,
2008

Six months ended
March 31,
2008Medicare

$
17,297,146

$
32,170,010Medi-Cal


13,256,236


24,067,014Managed care


954,193


1,656,679Self pay


512,318


938,636Other


376,233


850,015Total

$
32,396,126

$
59,682,354


Hospital
revenues depend upon inpatient occupancy levels, the medical and ancillary services and therapy programs ordered by physicians and provided to patients, the volume of outpatient
procedures and the charges or negotiated payment rates for such services. Charges and reimbursement rates for inpatient routine services vary depending on the type of services provided
(e.g., medical/surgical, intensive care or behavioral health) and the geographic location of the hospital. Inpatient occupancy levels fluctuate for various reasons, many of which are beyond our
control. The percentage of patient service revenue attributable to outpatient services has generally increased in recent years, primarily as a result of advances in medical technology that allow more
services to be provided on an outpatient basis, as well as increased pressure from Medicare, Medi-Cal and private insurers to reduce hospital stays and provide services, where possible, on
a less expensive outpatient basis. We believe that our experience with respect to our increased outpatient levels mirrors the general trend occurring in the health care industry and we are unable to
predict the rate of growth and resulting impact on our future revenues.

Patients
are generally not responsible for any difference between customary hospital charges and amounts reimbursed for such services under Medicare, Medicaid, some private insurance
plans, and managed care plans, but are responsible for services not covered by such plans, exclusions, deductibles or co-insurance features of their coverage. The amount of such
exclusions, deductibles and co-insurance has generally been increasing each year. Indications from recent federal and state legislation are that this trend will continue. Collection of
amounts due from individuals is typically more difficult than from governmental or business payers and we continue to experience an increase in uninsured and self-pay patients which
unfavorably impacts the collectability of our patient accounts thereby increasing our provision for doubtful accounts and charity care provided.

37

---



The
following table details operating data of our hospital services facilities for the three-month and six-month periods ended March 31, 2008:

Three months ended
March 31,
2008

Six months ended
March 31,
2008Total net revenues

$
32,396,126

$
59,682,354Operating income before income taxes


7,811,161


13,746,980Total assets as of March 31, 2008


74,676,002


74,676,002Average licensed beds


339


339Average available beds


331


331Inpatient admissions


3,742


7,067Average length of patient stay (days)


5.5


5.3Patient days


22,700


41,620Occupancy rate for licensed beds


73.4
%

68.0
%Occupancy rate for available beds


75.4
%

69.9
%


Operating
expenses of our Hospital Services segment include salaries, benefits and other compensation paid to physicians and health care professionals that are employees of our
hospitals; medical supplies; consultant and professional services; and provision for doubtful accounts.

General
and administrative expenses of our Hospital Services segment includes salaries, benefits and other compensation for our Hospital administrative employees, insurance, rent,
operating supplies, legal, accounting and marketing.

38

---



Results of Operations

IPA Management

The following table sets forth results of operations for our IPA Management segment for the three-month and six-month periods ended March 31, 2008
and 2007:

|                                         |                                       | Three months ended
March 31, |            |            |   | Six months ended
March 31, |            |       |      
|---------------------------------------- | ------------------------------------- | ---------------------------- | ---------- | ---------- | - | -------------------------- | ---------- | ----- | -----
|
|
|Managed care revenues:                   |                                       |                              |            |            |   |                            |            |       |      
|                                         | Capitation                            |                              | $          | 54,133,965 |   | $                          | 32,455,047 |       | 66.8 
|                                         | Fee for service                       |                              |            | 582,864    |   |                            | 516,999    |       | 12.7 
|                                         | Management fees                       |                              |            | 146,767    |   |                            | 193,102    |       | (24.0
|                                         | Other revenues                        |                              |            | 83,024     |   |                            | 161,838    |       | (48.7
|                                         |                                       |                              |            |            |   |                            |            |       |      
|                                         | Total managed care revenues           |                              |            | 54,946,620 |   |                            | 33,326,986 |       | 64.9 
|Managed care cost of revenues:           |                                       |                              |            |            |   |                            |            |       |      
|                                         | PCP capitation                        |                              |            | 9,605,144  |   |                            | 6,018,320  |       | 59.6 
|                                         | Specialist capitation                 |                              |            | 10,766,682 |   |                            | 4,820,145  |       | 123.4
|                                         | Claims expense                        |                              |            | 21,219,355 |   |                            | 14,411,274 |       | 47.2 
|                                         | Physician salaries                    |                              |            | 931,176    |   |                            | 741,854    |       | 25.5 
|                                         | Other cost of revenues                |                              |            | 308,098    |   |                            | 178,763    |       | 72.3 
|                                         |                                       |                              |            |            |   |                            |            |       |      
|                                         | Total managed care cost of revenues   |                              |            | 42,830,455 |   |                            | 26,170,356 |       | 63.7 
|                                         | Gross margin                          |                              |            | 12,116,165 |   |                            | 7,156,630  |       | 69.3 
|                                         | General and administrative expenses   |                              |            | 13,025,138 |   |                            | 9,081,430  |       | 43.4 
|                                         | Depreciation and amortization expense |                              |            | 1,211,972  |   |                            | 391,207    |       | 209.8
|                                         |                                       |                              |            |            |   |                            |            |       |      
|                                         | Total non-medical expenses            |                              |            | 14,237,110 |   |                            | 9,472,637  |       | 50.3 
|Income from unconsolidated joint venture |                                       |                              | 694,218    |            |   | 499,637                    |            | 38.9  | %    
|                                         |                                       |                              |            |            |   |                            |            |       |      
|Operating loss                           |                                       | $                            | (1,426,726 | )          | $ | (1,816,370                 | )          | (21.5 | )%   
|                                         |                                       |                              |            |            |   |                            |            |       |      

The following table sets forth selected operating items, expressed as a percentage of total revenue:

|                                         |                                       | Three months ended
March 31, |       | Six months ended
March 31, |      
|---------------------------------------- | ------------------------------------- | ---------------------------- | ----- | -------------------------- | -----
|
|Managed care revenues:                   |                                       |                              |       |                            |      
|                                         | Capitation revenue                    |                              | 98.5  | %                          | 97.3 
|                                         | Fee for service revenue               |                              | 1.1   | %                          | 1.6  
|                                         | Management fees                       |                              | 0.3   | %                          | 0.6  
|                                         | Other revenues                        |                              | 0.2   | %                          | 0.5  
|                                         |                                       |                              |       |                            |      
|                                         | Total managed care revenues           |                              | 100.0 | %                          | 100.0
|Managed care cost of revenues:           |                                       |                              |       |                            |      
|                                         | PCP capitation                        |                              | 17.5  | %                          | 18.1 
|                                         | Specialists capitation                |                              | 19.6  | %                          | 14.5 
|                                         | Claims expense                        |                              | 38.6  | %                          | 43.2 
|                                         | Physician salaries                    |                              | 1.7   | %                          | 2.2  
|                                         | Other cost of revenues                |                              | 0.6   | %                          | 0.5  
|                                         |                                       |                              |       |                            |      
|                                         | Total managed care cost of revenues   |                              | 77.9  | %                          | 78.5 
|                                         | Gross margin                          |                              | 22.1  | %                          | 21.5 
|                                         | General and administrative expenses   |                              | 23.7  | %                          | 27.2 
|                                         | Depreciation and amortization expense |                              | 2.2   | %                          | 1.2  
|                                         |                                       |                              |       |                            |      
|                                         | Total non-medical expenses            |                              | 25.9  | %                          | 28.4 
|Income from unconsolidated joint venture |                                       | 1.3                          | %     | 1.5                        | %    
|                                         |                                       |                              |       |                            |      
|Operating loss                           |                                       | (2.6                         | )%    | (5.5                       | )%   
|                                         |                                       |                              |       |                            |      

39

---



Three Months Ended March 31, 2008 Compared to Three Months Ended March 31, 2007

Capitation Revenue

Capitation revenue for the three months ended March 31, 2008 was $54,133,965, representing an increase of $21,678,917 or 66.8% from capitation revenue for
the three months ended March 31, 2007, of $32,455,047.

Exclusive
of the ProMed Acquisition, capitation revenue decreased by $1,453,794 or 4.5% from the three months ended March 31, 2007. We estimated that net membership growth from
the June 1, 2007 acquisition of ProMed contributed approximately $23,132,710 in increased capitation revenue during the fiscal 2008 period, as compared to the fiscal 2007 period. The decrease
was due to lower enrollment offset by increase in capitation rates.

Fee for service revenue

Fee for service revenue for the three months ended March 31, 2008 was $582,864 representing an increase of $65,865 or 12.7% from fee for service revenue
for the three months ended March 31, 2007, of $516,999.

The
increase in fee for service revenue during the fiscal 2008 period was primarily due to fluctuations in patient visits at our owned clinics.

Management fee revenue

Management fee revenue for the three months ended March 31, 2008 was $146,767, representing a decrease of $46,335 or 24.0% from management fee revenue for
the three months ended March 31, 2007, of $193,102.

The
decrease in management fee revenue during the fiscal 2008 period was primarily the result of the termination of a portion of our joint venture management contract related to
CalOPTIMA Medi-Cal and Healthy Family enrollees and an amendment to the Brotman Medical Center advisory contract which reduced our management involvement and the related fee.

Other revenue

Other revenue for the three months ended March 31, 2008 was $83,024, representing a decrease of $78,814 or 48.7% over other revenue for the three months
ended March 31, 2007, of $161,838.

Amounts
represent incentive payments from HMOs under "pay-per-performance" programs for quality medical care based on various criteria. The incentives are
recorded when such amounts are known.

The
decrease in other revenue during the 2008 period was primarily the result of the timing of pay-for-performance incentives from one of our contracted Health
Plans.

PCP Capitation Expense

Primary care physician ("PCP") capitation expense for the three months ended March 31, 2008 was $9,605,144, representing an increase of $3,586,824 or 59.6%
over PCP capitation expense for the three months ended March 31, 2007, of $6,018,320.

Exclusive
of the ProMed Acquisition, PCP capitation expense for the fiscal 2008 quarter decreased by $636,780 or 10.6%. We estimate that net membership growth from the June 1,
2007 acquisition of ProMed contributed approximately $4,223,605 in increased PCP capitation expense during the fiscal 2008 period, as compared to the fiscal 2007 period. We estimate that higher
capitation rates on our core business, exclusive of acquisitions, increased PCP capitation expense by approximately $211,000

40

---



during
the fiscal 2008 period as compared to the fiscal 2007 period. We estimate that member months declines related to our core business, exclusive of the acquisition, reduced PCP capitation expense
by approximately $848,000, during the fiscal 2008 period, as compared to the fiscal 2007 period.

Specialist Capitation Expense

Specialist Capitation expense for the three months ended March 31, 2008 was $10,766,682, representing an increase of $5,946,537 or 123.4% from specialist
capitation expense for the three months ended March 31, 2007, of $4,820,145.

Exclusive
of the ProMed Acquisition, specialist capitation expense for the fiscal 2008 quarter decreased by $445,824 or 9.2%. We estimate that net membership growth from the
June 1, 2007 acquisition of ProMed contributed approximately $6,392,361 in increased specialist capitation expense during the fiscal 2008 period, as compared to the fiscal 2007 period. We
estimate that higher capitation rates on our core business, exclusive of the acquisition, increased specialist capitation expense by approximately $233,000 during the fiscal 2008 period as compared to
the fiscal 2007 period. We estimate that member months declines related to our core business, exclusive of the acquisitions, reduced specialist capitation expense by approximately $679,000 during the
fiscal 2008 period, as compared to the fiscal 2007 period.

Claims Expense

Claims expense for the three months ended March 31, 2008 was $21,219,355, representing an increase of $6,808,081 or 47.2% over claims expense for the three
months ended March 31, 2007, of $14,411,274.

We
estimate that net membership growth from the June 1, 2007 acquisition of ProMed contributed approximately $6,964,488 in increased claims expense during the fiscal 2008 period,
as compared to the fiscal 2007 period. We estimate that higher claims per member rates on our core business, exclusive of acquisitions, increased claims expense by approximately $1,868,000 during the
fiscal 2008 period as compared to the fiscal 2007 period. We estimate that member months declines related to our core business, exclusive of the acquisition, reduced claims expense by approximately
$2,030,000 in the fiscal 2008 period, as compared to the fiscal 2007 period.

Physician Salaries Expense

Physician salaries expense for the three months ended March 31, 2008 was $931,176, representing an increase of $189,322 or 25.5% over physician salaries
expense for the three months ended March 31, 2007, of $741,854.

The
increase in physician salaries expense during the 2008 period was primarily the result of the conversion of certain contracted physicians from capitation to employment basis
effective third quarter of fiscal 2007.

Other Cost of Revenues

Other cost of revenues for the three months ended March 31, 2008 was $308,098, representing an increase of $129,335 or 72.3% from other cost of revenue for
the three months ended March 31, 2007, of $178,763. Exclusive of the ProMed acquisition however, other cost of revenue for the fiscal 2008 quarter decreased by $25,333.

The
decrease in other cost of revenue during the 2008 period was primarily the result of a lower amount of stop loss insurance premium charged by our insurance carrier.

41

---



Gross Margin

Medical care costs as a percentage of medical revenues (the medical care ratio) largely determine our gross margin. Our gross margin increased to 22.1% for the
three months ended March 31, 2008, from 21.5% for the three months ended March 31, 2007. Exclusive of the ProMed acquisition , our gross margin decreased to 21.0%.

The
decrease in our gross margin percentage between the fiscal 2008 and 2007 periods was primarily the result of increasing claims cost per member per month in fiscal 2008.

General and Administrative Expenses

General and administrative expenses were $13,025,138 for the fiscal 2008 period, representing 23.7% of total revenues, as compared with $9,081,430, or 27.2% of
total revenues, for the fiscal 2007 period.

Exclusive
of the ProMed Acquisition, general and administrative expenses were $10,947,530 for the fiscal 2008 quarter, representing 34.5% of total Prospect revenues. The increase in
general and administrative expenses during the fiscal 2008 quarter was primarily related to an increase in personnel and personnel related costs. This is due to the addition and upgrading of several
key positions as well as increases in outside professional fees related to audit, SOX and SEC reporting activities. In the 2008 period, the Company incurred approximately $1,484,000 in costs related
to the restatement of Alta's pre-acquisition financial statements and related SEC filings, the special investigation by the Company's audit committee, and lender forbearance activities.

Depreciation and Amortization

Depreciation and amortization expense for the three months ended March 31, 2008 increased to $1,211,972 from $391,207 for the same period of the prior
year. The increase of $820,765 was primarily due to the amortization of identifiable intangible assets related to the acquisition of ProMed and Alta, as well as additional depreciation expense for
increased capital expenditures.

Income from Unconsolidated Joint Venture

The income from unconsolidated joint venture for the three months ended March 31, 2008 increased to $694,218 from $499,637 for the same period of the prior
year. The increase resulted from the removal of certain minimum healthcare spending requirements in the CalOPTIMA OneCare program effective January 1, 2007 which increased the profitability of
the program.

Six months Ended March 31, 2008 Compared to Six months Ended March 31, 2007

Capitation Revenue

Capitation revenue for the six months ended March 31, 2008 was $108,216,088, representing an increase of $41,668,751 or 62.6% from capitation revenue for
the six months ended March 31, 2007, of $66,547,337.

Exclusive
of the ProMed Acquisition, capitation revenue decreased by $4,027,215 or 6.1% from the six months ended March 31, 2007. We estimated that net membership growth from the
June 1, 2007 acquisition of ProMed contributed approximately $45,695,965 in increased capitation revenue during the fiscal 2008 period, as compared to the fiscal 2007 period. The decrease is
comprised of three main factors: (i) effective January 1, 2007, the Medi-Cal and Healthy Family enrollees under the CalOPTIMA contract were reassigned from the AMVI/Prospect
Joint Venture directly to Prospect Medical Group. As a result, revenues and service costs related to these enrollees, who were previously included in income from unconsolidated joint venture (see
below), are reported as capitation revenue

42

---



and
managed care cost of revenue, respectively, beginning January 1, 2007. This change in reporting accounted for $1,243,485 of the increase in revenue in the 2008 fiscal period as compared to
the 2007 fiscal period, (ii) decrease in hospital shared risk revenue to $343,667 in the 2008 period as compared to $1,098,006 in the 2007 period, and (iii) decrease in membership months
offset by increase in capitation rates, which contributed to $5,264,264 in net decreased capitation.

Fee for service revenue

Fee for service revenue for the six months ended March 31, 2008 was $1,181,974 representing an increase of $282,095 or 31.3% from fee for service revenue
for the six months ended March 31, 2007, of $899,879.

The
increase in fee for service revenue during the 2008 period was primarily due to fluctuations in patient visits at our owned clinics.

Management fee revenue

Management fee revenue for the six months ended March 31, 2008 was $254,395, representing a decrease of $202,774 or 44.4% from management fee revenue for
the six months ended March 31, 2007, of $457,169.

The
decrease in management fee revenue during the fiscal 2008 quarter was primarily the result of the termination of a portion of our joint venture management contract related to
CalOPTIMA, Medi-Cal and Healthy Family enrollees and an amendment to the Brotman Medical Center advisory contract which reduced our management involvement and the related fee.

Other revenues

Other revenues for the six months ended March 31, 2008 was $268,548, representing an increase of $17,950 or 7.2% over other revenue for the six months
ended March 31, 2007, of $250,598.

Amounts
represent incentive payments from HMOs under "pay-per-performance" programs for quality medical care based on various criteria. The incentives are
recorded when such amounts are known. The increase in other revenue during the fiscal 2008 period was primarily the result of timing of the incentives received from our contracted Health Plans.

PCP Capitation Expense

Primary care physician ("PCP") capitation expense for the six months ended March 31, 2008 was $19,308,611, representing an increase of $7,413,692 or 62.3%
over PCP capitation expense for the six months ended March 31, 2007, of $11,894,919.

We
estimate that net membership growth from the June 1, 2007 acquisition of ProMed contributed approximately $8,236,420 in increased PCP capitation expense during the fiscal 2008
period, as compared to the fiscal 2007 period. We estimate that higher capitation rates on our core business, exclusive of acquisitions, increased PCP capitation expense by approximately $242,623
during the fiscal 2008 period as compared to the 2007 period. We estimate that member months declines related to our
core business, exclusive of the acquisition, reduced PCP capitation expense by approximately $1,065,351 during the fiscal 2008 period, as compared to the fiscal 2007 period.

Specialist Capitation Expense

Specialist capitation expense for the six months ended March 31, 2008 was $21,609,237, representing an increase of $11,508,009 or 113.9% from specialist
capitation expense for the six months ended March 31, 2007, of $10,101,228.

43

---



We
estimate that net membership growth from the June 1, 2007 acquisition of ProMed contributed approximately $12,733,987 in increased specialist capitation expense during the
fiscal 2008 period, as compared to the fiscal 2007 period. We estimate that lower capitation rates on our core business, exclusive of the acquisition, reduced specialist capitation expense by
approximately $321,276 during the fiscal 2008 period as compared to the fiscal 2007 period. We estimate that member months declines related to our core business, exclusive of the acquisitions, reduced
specialist capitation expense by approximately $904,702 during the fiscal 2008 period, as compared to the fiscal 2007 period.

Claims Expense

Claims expense for the six months ended March 31, 2008 was $44,150,050, representing an increase of $15,768,649 or 55.6% over claims expense for the six
months ended March 31, 2007, of $28,381,401.

We
estimate that net membership growth from the June 1, 2007 acquisition of ProMed contributed $14,664,630 in increased claims expense during the fiscal 2008 period, as compared
to the fiscal 2007 period. We estimate that higher claims per member rates on our core business, exclusive of acquisitions, increased claims expense by approximately $3,639,540 during the fiscal 2008
period as compared to the fiscal 2007 period. We estimate that member months declines related to our core business, exclusive of the acquisition, reduced claims expense by approximately $2,541,940 in
the fiscal 2008 period, as compared to the fiscal 2007 period.

Physician Salaries Expense

Physician salaries expense for the six months ended March 31, 2008 was $2,003,712, representing an increase of $633,406 or 46.2% over physician salaries
expense for the six months ended March 31, 2007, of $1,370,306.

The
increase in physician salaries expense during the fiscal 2008 period was primarily the result of the conversion of certain contracted physicians from capitation to employment basis
effective third quarter of fiscal 2007.

Other Cost of Revenues

Other cost of revenues for the six months ended March 31, 2008 was $147,955, representing a decrease of $310,573 or 67.7% over other cost of revenue for
the six months ended March 31, 2007, of $458,528.

The
decrease in other cost of revenues during the fiscal 2008 period was primarily the result of a recovery in connection with the stop loss insurance and a lower amount of stop loss
insurance premium charged by our insurance carrier.

Gross Margin

Medical care costs as a percentage of medical revenues (the medical care ratio) largely determine our gross margin. Our gross margin decreased to 20.7% for the
six months ended March 31, 2008, from 23.4% for the six months ended March 31, 2007.

The
decrease in our gross margin percentage between the fiscal 2008 and fiscal 2007 periods was primarily the result of the increasing claims cost per member per month in fiscal 2008.

General and Administrative Expenses

General and administrative expenses were $24,714,424 for the fiscal 2008 period, representing 22.5% of total revenues, as compared with $17,158,498, or 25.2% of
total revenues, for the 2007 period.

44

---



Exclusive
of the ProMed Acquisition, general and administrative expenses were $20,887,829 the fiscal 2008 period, representing 32.6% of total Prospect revenues. The increase in general
and administrative expenses during the fiscal 2008 quarter primarily related to an increase in personnel and personnel related costs. This is due to the addition and upgrading of several key positions
as well as increases in outside professional fees related to audit, SOX and SEC reporting activities. In the 2008 period, the Company incurred approximately $1,949,000 in costs related to the
restatement of Alta's pre-acquisition financial statements and related SEC filings, the special investigation by the Company's audit committee, and lender forbearance activities.

Depreciation and Amortization

Depreciation and amortization expense for the six months ended March 31, 2008 increased to $2,413,736 from $783,026 for the same period of the prior year.
The increase of $1,630,710 was primarily due to the amortization of identifiable intangible assets related to the acquisition of ProMed and Alta, as well as additional depreciation expense for
increased capital expenditures.

Income From Unconsolidated Joint Venture

The income from unconsolidated joint venture for the six months ended March 31, 2008 increased to $1,168,959 from $763,579 for the same period of the prior
year. The increase resulted from the removal of certain minimum healthcare spending requirements in the CalOPTIMA OneCare program effective January 1, 2007 which increased the profitability of
the program.

Hospital Services

The following table sets forth the results of operations for our Hospital Services segment and is used in the discussion below for the three-month and
six-month periods ended March 31, 2008:

Three months
ended
March 31,

Six months
ended
March 31,2008

2008Net patient revenues:Medicare

$
17,297,146

$
32,170,010Medi-Cal


13,256,236


24,067,014Managed care


954,193


1,656,679Self pay


512,318


938,636Other


376,233


850,015Total net patient revenues


32,396,126


59,682,354Hospital operating expenses:Salaries, wages and benefits


15,063,696


28,942,386Other operating expenses


1,868,772


3,534,633Supplies expense


2,268,317


4,177,582Provision for doubtful accounts


1,512,030


1,860,809Lease and rental expense


254,162


452,915Total hospital operating expenses


20,966,977


38,968,325General and administrative expenses


2,911,418


5,535,410Depreciation and amortization expense


706,570


1,431,639Total non-medical expenses


3,617,988


6,967,049Operating income

$
7,811,161

$
13,746,980


45

---



The
following table sets forth selected operating items, expressed as a percentage of total revenue:

Three Months
Ended
March 31,

Six Months
Ended
March 31,2008

2008Net patient revenues:Medicare

53.4
%
53.9
%Medi-Cal

40.9
%
40.3
%Managed care

2.9
%
2.8
%Self pay

1.6
%
1.6
%Other

1.2
%
1.4
%Total net patient revenues

100.0
%
100.0
%Hospital operating expenses:Salaries, wages and benefits

46.5
%
48.5
%Other operating expenses

5.8
%
5.9
%Supplies expense

7.0
%
7.0
%Provision for doubtful accounts

4.7
%
3.1
%Lease and rental expense

0.8
%
0.8
%Total hospital operating expenses

64.7
%
65.3
%General and administrative expenses

9.0
%
9.3
%Depreciation and amortization expense

2.2
%
2.4
%Total non-medical expenses

11.2
%
11.7
%Operating income

24.1
%
23.0
%


With
the acquisition of Alta on August 8, 2007, the Company now owns and operates four community-based hospitals with a combined 339 licensed beds served by 351
on-staff physicians. For the three-month and six-month periods ended March 31, 2008, our Hospital Services segment reported operating income of $7,811,161 and
$13,746,980 on net patient revenues of $32,396,126 and $59,682,354, respectively. Net patient service revenues increased $5,109,898 or 18.7% from $27,286,228 in the first quarter to $32,396,126 in the
second quarter. Hospital operating expenses increased $2,965,630 or 16.5% from $18,001,347 in the first quarter to $20,966,977 in the second quarter. The sequential growth reflects increased patient
census and outpatient services, which primarily
reflects seasonality in our hospital operations. The hospital industry typically experiences increased patient volume in the first calendar quarter after the holiday season.

Alta
was not part of the consolidated results of the Company during the three-month and six-month periods ended March 31, 2007 and, as such, comparative quarterly
information has not been provided.

Consolidated Interest Expense and Amortization of Deferred Financing Costs

Interest expense and amortization of deferred financing costs, for the three months and the six months ended March 31, 2008 increased to $5,382,991 and
$9,679,078 from $234,598 and $501,579, respectively, for the same periods of the prior year. The increase in net interest expense during the fiscal 2008 period was primarily due to additional interest
expense on the $155 million senior secured credit facility entered into on August 8, 2007 to re-finance the ProMed Acquisition debt and to finance the Alta Acquisition. For
the period January 28, 2008 through April 10, 2008, interest was assessed at default rates of 11.4% with respect to the first lien term loan and 15.4% with respect to the second lien
term loan. In addition, the Company paid $762,500 in forbearance fees to the lenders in February 2008 which are also included in interest expense in the 2008 periods.

46

---



Loss On Interest Rate Swaps

Loss on interest rate swaps of $876,680 represented losses on an interest rate swap that was not yet subject to hedge accounting and that were charged to earnings
in the first quarter of fiscal 2008. Effective December 31, 2007, this interest rate swap was designated as a cashflow hedge with subsequent changes in fair value recorded in other
comprehensive loss. There were no interest rate swaps in place during the fiscal 2007 period.

Provision for Income Taxes

We reported income tax expense of $419,525 and $137,168, in the three-month and six-month periods ended March 31, 2008, respectively, compared
to a benefit of $736,690
and $511,338, in the same periods last year, respectively. The effective tax rates were 36% in the 2008 periods, compared to 40% in the same periods last year. The lower effective tax rates in the
fiscal 2008 periods were due to non-deductible expenses which reduced the taxable loss and the related income tax benefit.

Liquidity and Capital Resources

Our primary source of cash from operations was derived from capitation revenue, healthcare services provided on a fee-for-service basis at
our clinics, and management fee revenue generated in our IPA Management segment, net patient revenues generated in our Hospital Services segment and from investment income. Our primary uses of cash
include the payment of expenses related to health care services and G&A expenses in both our IPA Management and Hospital Services segments. Our IPA Management segment generally receives capitation
revenue in advance of payment of capitation expenses and claims for related health care services. Our Hospital Services segment receives payments generally 30 to 90 days after the medical care
is rendered. For some accounts and payor programs, the time lag between service and reimbursement can exceed one year.

Our
investment policies are designed to preserve principal, maintain liquidity for operations and statutory requirements, and maximize investment return. As of March 31, 2008 we
invested a substantial portion of our cash in U.S. bank certificate of deposits with an average maturity of approximately 115 days, and overnight and high yield money market funds. All of these
amounts are classified as current assets and included in cash and cash equivalents in the accompanying balance sheets. We are also required by some of our HMO contracts to set aside certain amounts in
restricted certificates of deposit to secure our ability to pay medical claims. These restricted certificates of deposit, with an average maturity of approximately 115 days as of
March 31, 2008, are included in current investments in the accompanying financial statements as they are restricted for payment of current liabilities.

Net
cash provided by operations was $1,699,477 for the six months ended March 31, 2008 compared to net cash used in operations of $1,416,482 for the six months ended
March 31, 2007. The increase in net cash provided by operations for the six months ended March 31, 2008 when compared to the six months ended March 31, 2007 was due to the
following factors:



47

---









Net
cash used in investing activities was $903,013 for the six months ended March 31, 2008 and $529,549 for the six months ended March 31, 2007. Investing activities
primarily included purchases of fixed
assets, a use of $921,460 in the six months ended March 31, 2008 compared to a use of $358,674 in the six months ended March 31, 2007.

Net
cash provided by financing activities was $1,242,983 for the six months ended March 31, 2008 compared to cash used in financing activities of $1,944,247 for the six months
ended March 31, 2007. The increase in net cash provided by financing activities was primarily due to borrowing activities. In the 2007 period, we repaid $3,900,000 in borrowings. In the 2008
period, repayments, net of borrowings on the line of credit, were not significant:

We
also received $1,200,000 in proceeds from common stock issuances related to stock option exercises during the six months ended March 31, 2008, compared to $1,726,385 in the six
months ended March 31, 2007;

At
March 31, 2008, we had positive working capital of $138,870 as compared to positive working capital of $2,248,634 at September 30, 2007. At March 31, 2008 and
September 30, 2007, cash and cash equivalents were $23,638,717 and $21,599,270, respectively. The reduction in working capital at March 31, 2008 is primarily due to accrued dividends on
our preferred shares, which totaled $4,987,308 at March 31, 2008 compared to $1,122,319 at September 30, 2007. These dividends are included in current liabilities but will not be paid
upon conversion to common shares if approved by our shareholders at the next scheduled shareholders meeting. Current debt obligations have also increased $2,750,000 from September 30, 2007 due
to additional net borrowings on the line of credit. Our refundable income taxes have decreased due to taxable income reported by our affiliated physician organizations which file a separate tax
return and whose income cannot be offset by losses from other entities within our organization.

The
decrease in working capital is also due to seasonality of our hospital operations. Revenues from our Hospital Services segment increased $5,109,898 or 18.7% from $27,286,228 in the
first quarter of 2008 to $32,396,126 in the second quarter. Hospital operating expenses increased $2,965,630 or 16.5% from $18,001,347 in the first quarter to $20,966,977 in the second quarter. The
increased revenues have resulted in a $3,590,650 increase in net patient accounts receivable, which are generally collected 30 to 90 days from the billing date or longer for some payors and
service types. However, hospital operating expenses, which are primarily payroll, are paid on a current basis.

48

---



Our
subsidiaries are required to maintain minimum capital prescribed by various HMOs with whom we contract. As of March 31, 2008, all of our subsidiaries were in compliance with
the minimum capital requirements. Barring any change in regulatory requirements, we believe that we will continue to be in compliance with these requirements at least through the end of fiscal 2008.
We also believe that our
cash resources and internally generated funds will be sufficient to support our operations, regulatory requirements, debt service, and capital expenditures for at least the next 12 months.

Recent Operating Results and Credit Facility

During the fourth quarter of fiscal 2007, the Company recorded a non-cash impairment charge of approximately $38.8 million to write off
goodwill and intangibles within the IPA Management segment, which resulted in losses in the Company's core operations during 2007, although operating activities have generated positive cash flows from
2005 to 2007. The improvement of the Company's core operations and the successful integration of its newly acquired subsidiaries has required and will continue to require significant investment and
management attention. The Company is undertaking a review of its operations to improve profitability and efficiency and to reduce costs, which may include the divestiture of non-strategic
assets.

The
Company is subject to certain financial and administrative covenants, cross default provisions and other conditions required by the loan agreements with the lenders, including a
maximum senior debt/EBITDA ratio and a minimum fixed-charge coverage ratio, each computed quarterly based on consolidated trailing twelve-month operating results, including the
pre-acquisition operating results of any acquired entities. The administrative covenants and other restrictions with which the Company must comply include, among others, restrictions on
additional indebtedness, incurrence of liens, engaging in business other than the Company's primary business, paying certain dividends, acquisitions and asset sales. The credit facility provides that
an event of default will occur if there is a change in control.

While
the Company has met all debt service requirements timely, it did not comply with certain financial and administrative covenants as of September 30, 2007 and for periods
thereafter as discussed in Note 6 of the condensed consolidated financial statements. The Company did not make timely filings of its Form 10-K for the year ended
September 30, 2007 and its Forms 10-Q for the quarters ended December 31, 2007 and March 31, 2008. Effective January 16, 2008, trading of the Company's
shares was suspended.

On
February 13, 2008, April 10, 2008 and May 14, 2008, the Company and its lenders entered into forbearance agreements, whereby the lenders agreed not to exercise
their rights under the credit facility through May 15, 2008, subject to satisfaction of specified conditions. On May 15, 2008, The Company and its lenders entered into an agreement to
waive past covenant violations and to amend the financial covenant provisions prospectively. Effective May 15, 2008, the maximum senior debt/EBITDA ratios were increased to levels ranging from
3.90 to 7.15 for monthly reporting periods from April 30, 2008 through June 30, 2009 and were increased to levels ranging from 3.30 to 3.75 beginning with the September 30, 2009
quarterly reporting period through maturity of the term loan. The minimum fixed charge coverage ratios were reduced to levels ranging from 0.475 to 0.925 for monthly reporting periods from
April 30, 2008 through June 30, 2009 and were reduced to levels ranging from 0.85 to 0.90 beginning with the September 30, 2009 quarterly reporting period through maturity of the
term loan. The Company is also required to meet a minimum EBITDA for future monthly reporting periods from
April 30, 2008 through June 30, 2009 and the remaining quarterly periods through maturity of the term loan. In addition, the Company is required to, among other conditions, file its
Form 10-K for the year ended September 30, 2007 and Forms 10-Q for the quarters ended December 31, 2007 and March 31, 2008 by June 16,
2008. Failure to perform any obligation under the waiver and the amended credit facility agreement constitutes an additional event of default.

49

---



As
discussed in Note 6, for the period January 28, 2008 through April 10, 2008, interest was assessed at default interest rates. Under the April 2008 forbearance
agreement, the applicable margin on the first and second lien term loans and the revolver were permanently increased effective April 10, 2008. During the forbearance periods, the Company had
limited or no access to the line of credit. The Company also agreed to pay certain fees and expenses to the lenders.

Management
has implemented a turnaround plan to improve the operating results of the IPA Management segment, including measures to retain and increase enrollment, increase health plan
reimbursements and reduce medical costs. The Company also plans to divest non-strategic assets to reduce debt service. Management believes that it will be able to comply with all
covenants, as modified, at least for the next twelve months. The Company has filed the 2007 Form 10-K on June 2, 2008 and the December 31, 2007 Form 10-Q on June 9,
2008 and expects to be able to make timely filing of its Form 10-Q for the quarter ended June 30, 2008 and its Form 10-K for the year ended
September 30, 2008. As such, scheduled payments due after twelve months have been classified as non-current liabilities at September 30, 2007 and March 31, 2008.

However,
there can be no assurance that this turnaround plan will have a successful outcome and that the Company will be able to meet all of the financial covenants and other conditions
required by the loan agreements for future periods. The lenders may not provide forbearance or grant waivers of future covenant violations and could require full and immediate repayment of the loans,
which would negatively impact the Company's liquidity, ability to operate and ability to continue as a going concern.

Contractual Obligations

In our annual report on Form 10-K filed on June 2, 2008, we reported on our contractual obligations as of that date. There have been no
material changes to our contractual obligations since that report.

Critical Accounting Policies

In Part II, Item 7 of our Form 10-K, under the heading "Critical Accounting Policies," we have provided a discussion of the
critical accounting policies that management believes affect its more significant judgments and estimates used in the preparation of our Consolidated Financial Statements.

When
we prepare our consolidated financial statements, we use estimates and assumptions that may affect reported amounts and disclosures. The determination of our liability for medical
claims and other health care costs payable is particularly important to the determination of our financial position and results of operations and requires the application of significant judgment by
our management and, as a result, is subject to an inherent degree of uncertainty.

Our
medical care costs include actual historical claims experience and estimates for medical care costs incurred but not reported to us ("IBNR"). We, together with our independent
actuaries, estimate medical claims liabilities using actuarial methods based upon historical data adjusted for payment patterns, cost trends, product mix, utilization of health care services and other
relevant factors. The estimation methods and the resulting reserves are frequently reviewed and updated, and adjustments, if necessary, are reflected in the period known. While we believe our
estimates are adequate, it is possible that future events could require us to make significant adjustments or revisions to these estimates. In assessing the adequacy of accruals for medical claims
liabilities, we consider our historical experience, the terms of existing contracts, our knowledge of trends in the industry, information provided by our customers and information available from other
sources as appropriate.

The
most significant estimates involved in determining our claims liability concern the determination of claims payment completion factors and trended per member per month cost
estimates.

50

---



We
consider historical activity for the current month, plus the prior 24 months, in our IBNR calculation. For the months of service five months prior to the reporting date and
earlier, we estimate our outstanding claims liability based upon actual claims paid, adjusted for estimated completion factors. Completion factors seek to measure the cumulative percentage of claims
expense that will have been paid for a given month of service as of a date subsequent to that month of service. Completion factors are based upon historical payment patterns. For the four months of
service immediately prior to the reporting date, actual claims paid are not a reliable measure of our ultimate liability, given the delay inherent between the patient/physician encounter and the
actual submission of a claim for payment. For these months of service we estimate our claims liability based upon trended per member per month ("PMPM") cost estimates. These estimates reflect recent
trends in payments and expense, utilization patterns, authorized services and other relevant factors. The following tables reflect (i) the change in
our estimate of claims liability as of March 31, 2008 that would have resulted had we changed our completion factors for all applicable months of service included in our IBNR calculation
(i.e., the preceding 5th through 25th months) by the percentages indicated; and (ii) the change in our estimate of claims liability as of
March 31, 2008 that would have resulted had we changed trended PMPM factors for all applicable months of service included in our IBNR calculation (i.e., the preceding 1st through
4th months) by the percentages indicated. Changes in estimate of the magnitude indicated in the ranges presented are considered reasonably likely.

Increase (Decrease) in
Estimated Completion Factors

Increase (Decrease) in
Accrued Medical Claims
Payable(3)%

$
4,712,000(2)%

$
3,141,000(1)%

$
1,570,0001%

$
(1,570,000
)2%

$
(3,141,000
)3%

$
(4,712,000
)


|
|

Increase (decrease) In
trended PMPM factors

Increase (Decrease) in
Accrued Medical Claims
Payable(3)%

$
(806,000
)(2)%

$
(537,000
)(1)%

$
(269,000
)1%

$
269,0002%

$
537,0003%

$
806,000


Additionally,
for each 1% (hypothetical) difference between our March 31, 2008 estimated claims liability (of $23,226,000) and the actual claims incurred run-out,
pre-tax income for the six months ended March 31, 2008 would increase or decrease by approximately $232,000 or approximately $0.02 per diluted share.

51

---





The following table shows the components of the change in medical claims and benefits payable for the six months ended March 31, 2008 and 2007:

Six months ended
March 31,2008

2007IBNR as of beginning of period

$
22,638,960

$
11,400,000Health care claims expense incurred during the periodRelated to current year


46,352,283


28,717,324Related to prior years


(2,202,233
)

(335,923
)Total incurred


44,150,050


28,381,401Health care claims paid during the periodRelated to current year


(25,263,677
)

(16,639,645
)Related to prior years


(18,298,954
)

(9,976,756
)Total paid


(43,562,631
)

(26,616,401
)IBNR as of end or period

$
23,226,379

$
13,165,000


Bracketed
amounts reported in the table above for the incurred related to prior periods result from claims being ultimately settled for amounts less than originally estimated (a
favorable development). A positive amount reported for incurred related to prior periods would result from claims ultimately being settled for amounts greater than originally estimated (an unfavorable
development).

Through
March 31, 2008, the $2,202,233 changes in estimate related to IBNR as of September 30, 2007 represented approximately 9.7% of the IBNR balance as of
September 30, 2007, approximately 3.2% of claims expense, and after consideration of tax effect, approximately 3.9% of net loss for the year then ended. The $2,202,233 favorable claims
development in the 2008 period includes approximately $749,000 of reimbursements from the health plans for insured services and $414,000 in recovery of claims overpayments.

Through
March 31, 2007, the $335,923 changes in estimate related to IBNR as of September 30, 2006 represented approximately 2.9% of the IBNR balance as of
September 30, 2006, approximately 0.7% of claims expense, and after consideration of tax effect, approximately 4.1% of net income for the year then ended.

Past
fluctuations in the IBNR estimates might also be a useful indicator of the potential magnitude of future changes in these estimates. Quarterly IBNR estimates include provisions for
adverse development based on historical volatility. We maintain similar provisions at each quarter end.

Inflation

According to U.S. Bureau of Labor Statistics Data, the national health care cost inflation rate has exceeded the general inflation rate for the last four years.
We use various strategies to mitigate the negative effects of health care cost inflation. Specifically, we try to control medical and hospital costs through contracts with independent providers of
health care services. Through these contracted providers, we emphasize preventive health care and appropriate use of specialty and hospital services.

While
we currently believe our strategies to mitigate health care cost inflation will continue to be successful, competitive pressures, new health care and pharmaceutical product
introductions, demands from health care providers and customers, applicable regulations or other factors may affect our ability to control health care costs.

52

---



Item 3.    Quantitative and Qualitative Disclosures About Market Risk.

Concentrations of Credit Risk

Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash and cash equivalents, receivables, restricted cash
and debt.

As
of March 31, 2008, we had cash and cash equivalents of $23,638,717. Cash equivalents consist of highly liquid securities with original maturities of up to three months. We
invest a substantial portion of our cash equivalents in U.S. bank certificate of deposits and overnight, high yield money market funds. Our cash is held at financial institutions with strong credit
ratings. While the amounts at certain institutions exceed the $100,000 federal insurance limit, we have reviewed the financial condition of these institutions and the issues of the securities on a
periodic basis and do not believe there is a high level of risk. As of March 31, 2008, we had $636,592 of investments, primarily consisting of restricted, interest-bearing certificates of
deposit required by various HMOs with whom we do business. These investments are subject to interest rate risk and will decrease in value if the market rates increase. All non-restricted
investments are maintained at fair market value on the balance sheet. Although money market mutual funds are not insured, they are not typically subject to material market risk as these funds are
highly regulated as to the diversification of the portfolio, maturities and credit ratings of individual securities that the fund may invest in. In addition, we have the ability to hold these
investments until maturity, and as a result, we would not expect the value of these investments to decline significantly as a result of a sudden change in market interest rates. Declines in interest
rates over time will reduce our investment income. Assuming a hypothetical 10% change in interest rates, there would be no material impact on our future earnings and cash flows related to these
instruments, or their fair value.

We
financed our acquisitions through variable-rate debt. In the normal course of business, we have exposures to interest rate risk from our long-term debt. To
manage these risks, we have entered into derivative instruments such as interest rate swaps. We do not hold or issue financial instruments for trading purposes. In fiscal 2008, our derivative
instruments consisted of two interest rate swaps designated as cash flow hedges. These interest rate swaps are highly sensitive to fluctuations in interest rates. During the six months ended
March 31, 2008, the swaps have declined in value totaling $8.8 million, of which $3.9 million occurred during the quarter ended December 31, 2007 and $4.9 million
occurred during the quarter ended March 31, 2008.

At
March 31, 2008, we had $147 million of borrowings under variable interest rate facilities. Under the interest rate swap agreements entered into in May 2007 in connection
with the ProMed acquisition and in September 2007 in connection with the Alta acquisition, the notional amounts of these swaps are scheduled to decline in order to reflect certain scheduled and
anticipated principal payments under the term loan facilities. Under these swaps, we are required to make quarterly fixed rate payments to the counterparties calculated on the notional amount of the
swap and the interest rate for the particular swap, while the counterparties are obligated to make certain quarterly floating rate payments to us referencing the same notional amount. Our interest
rate swaps effectively convert the variable-rate debt to fixed-rate debt at a blended average LIBOR rate of 5.13% plus the applicable margin through their maturities.
Notwithstanding the terms of the interest rate swap transactions, we are ultimately obligated for all amounts due and payable under the existing credit facility. For terms relating to our
long-term debt, see Note 6 to the Condensed Consolidated Financial Statements.

Item 4.    Controls and Procedures.

Disclosure Controls and Procedures:Our management is responsible for establishing and maintaining
effective internal control over financial reporting as defined in Rules 13a-15(f) under the Securities Exchange Act of 1934. Our internal control over financial reporting is
designed to provide reasonable assurance to our management and board of directors regarding the preparation and fair

53

---



presentation
of published financial statements. We maintain controls and procedures designed to ensure that we are able to collect the information we are required to disclose in the reports we file
with the Securities and Exchange Commission, and to process, summarize and disclose this information within the time periods specified in the rules of the Securities and Exchange Commission.

Evaluation of Disclosure Controls and Procedures:Our management, with the participation of our Chief
Executive Officer and our Chief Financial Officer, conducted an evaluation of our disclosure controls and procedures (as defined in Rules 13(a)-15(e) and 15d-15(e) under
the Securities Exchange Act of 1934 (the "Exchange Act") which are designed to ensure that information required to be disclosed in the reports that we file or submit under the Exchange Act is
appropriately recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission's rules and forms. This evaluation was conducted as of
March 31, 2008, the end of the period covered by this report. Based on this evaluation, in light of the material weaknesses in internal control over financial reporting as of
September 30, 2007 and which have not been fully remediated as of March 31, 2008 as discussed below, our principal executive officer and our principal financial officer concluded that
our disclosure controls and procedures were not effective as of the evaluation date.

Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can
provide only reasonable assurance with respect to financial statement preparation and presentation.

Changes in Internal Controls:The principal executive officer and principal financial officer have
concluded that, other than the specific changes identified in this Item 9A in the Form 10-K for the year ended September 30, 2007 and as discussed under "Remediation Steps to
Address Material Weaknesses" below, there have been no changes in our internal control over financial reporting during the quarter ended March 31, 2008 that have materially affected, or are
reasonably likely to materially affect, our internal controls over financial reporting.

Summary of Material Weaknesses in Internal Control Over Financial Reporting:Shortly after our
August 8, 2007 acquisition of Alta Hospitals System, LLC ("Alta"), we determined that there were certain material errors in Alta's previously issued financial statements for its fiscal
year ended December 31, 2006, and that material adjustments were needed to be made to Alta's interim financial statements as of and for the six months ended June 30, 2007. The material
weaknesses noted were in the areas of recording reimbursements due from third-party payors related to open cost report years; accounting for receivables from government disproportionate share
programs; and valuation of general hospital accounts receivable balances.

These
areas involve complex accounting considerations and require significant knowledge and experience in hospital financial reporting and reimbursement. Alta did not have the necessary
finance personnel with specific expertise in these complex areas to evaluate all appropriate data and accounting considerations related to these areas, and knowledgeable personnel capable of
overseeing and evaluating work performed by outside consultants working on Alta's behalf. These deficiencies resulted in errors in the preparation and review of Alta's financial statements and related
disclosures and resulted in the restatements to Alta's financial statements for the year ended December 31, 2006 and in adjustments to Alta's interim financial statements as of and for the six
months ended June 30, 2007.

During
our review of these material weaknesses in Alta's internal control over financial reporting, we have identified the reasons for the material weaknesses and have taken, and intend
to continue taking, steps to strengthen Alta's internal control over financial reporting, as described in more detail below. These material weaknesses have not been fully remediated as of
March 31, 2008.

Our
Audit Committee engaged independent counsel, who, together with various advisers, assisted the Audit Committee in conducting an extensive investigation into the events that gave rise
to the misstatements in the Alta financial statements for the year ended December 31, 2006. The Audit

54

---



Committee
concluded the investigation in March 2008 and did not find any intentional wrongdoing in the preparation of the Alta financial statements, but confirmed the need for improvements in internal
control and control over financial reporting, as more fully discussed below.

As
a result of the significant acquisitions we completed in 2007, we have also undergone significant changes in our corporate and financial reporting structure. We now have a
multi-location, multi-tier reporting and consolidation process with decentralized accounting functions at each of our reporting units. As a result of these changes, along with the
deficiencies relating to Alta as discussed above, we did not make timely filings of our Form 10-K for the year ended September 30, 2007 and Forms 10-Q for
the quarters ended December 31, 2007 and March 31, 2008. We filed our Form 10-K on June 2, 2008 and our Form 10-Q for the quarter ended
December 31, 2007 on June 9, 2008. Following the 2007 acquisitions, we have expended significant efforts on financial reporting activities and integration of operations, expansion of our
disclosure controls and procedures and internal control systems to address, among other things, operations at multiple sites.

Remediation Steps to Address Material Weaknesses:Based on findings of material weaknesses in our
internal control over financial reporting as of March 31, 2008 as described above, we have taken steps to strengthen our internal controls over the more complex accounting areas, namely,
recording of reimbursements due from third-party payors, accounting for receivables from government disproportionate share programs, and valuation of general hospital accounts receivable balances. We
have significantly added to the expertise and depth of personnel within the Alta finance department, including the appointment of a highly qualified Chief Financial Officer, with specific and
significant expertise in the critical areas identified above. We also intend to expand our financial accounting and reporting team at our corporate location, including the establishment of an internal
audit function, to strengthen the overall financial statement close process and to provide additional oversight on financial accounting and reporting matters throughout our organization. However, not
all of these remediation steps were in place as of March 31, 2008 and, as such, the conclusion of management is that material weaknesses existed as of that date. We intend to address the
remaining actions required to remediate our existing weaknesses as part of our ongoing efforts to improve our control environment. As discussed, we have been and continue to be engaged in efforts to
improve our internal control over financial reporting. These measures include, but are not limited to, the following:



Sarbanes-Oxley 404 Compliance:We have begun a detailed assessment of our internal controls as called
for by the Sarbanes-Oxley Act of 2002. We are still in the evaluation of design phase. We have supplemented our internal project team with the services of an outside specialist. Although we have made
this project a priority for the company, there can be no assurances that all material weaknesses that may be identified and validated will be remediated before the required due date for management to
report on internal controls of September 30, 2008.

55

---





PART IIOTHER INFORMATION

Item 1.    Legal Proceedings.

We and our affiliated physician organizations are parties to legal actions arising in the ordinary course of business. We believe that liability, if any, under
these claims will not have a material adverse effect on our consolidated financial position or results of operations.

Item 1A.    Risk Factors.

The following risk factors, although discussed in Management's Discussion and Analysis of Financial Condition and Results of Operations in our
Form 10-K filed on June 2, 2008, were not included in the list of risk factors in Item 1A of that report and have therefore been included here:

Our revenue and profitability may be significantly reduced or eliminated if management is unable to successfully execute the turnaround plan to improve the operating results of
our IPA Management segment.

We have implemented a turnaround plan to improve the operating results of our IPA Management segment, including measures to retain and increase enrollment,
increase health plan reimbursements
and reduce medical costs. If we are unable to successfully execute the turnaround plan, our revenue and profitability may be significantly reduced or eliminated.

There can be no assurance that all identified material weaknesses in our internal controls will be remediated before the required due date under the Sarbanes-Oxley Act of 2002
for management to report on internal controls.

While we have begun a detailed assessment of our internal controls as called for by the Sarbanes-Oxley Act of 2002, there can be no assurance that all identified
material weaknesses will be remediated before the September 30, 2008 due date for management to report on internal controls.

Item 2.    Unregistered Sales of Equity Securities and Use of Proceeds.

None.

Item 3.    Defaults Upon Senior Securities.

The Company is subject to certain financial and administrative covenants, cross default provisions and other conditions required by the loan agreements with the
lenders, including a maximum senior debt/EBITDA ratio and a minimum fixed-charge coverage ratio, each computed quarterly based on consolidated trailing twelve-month results, including the
pre-acquisition results of any acquired entities. The administrative covenants and other restrictions with which the Company must comply include, among others, restrictions on additional
indebtedness, incurrence of liens, engaging in business other than the Company's primary business, paying certain dividends, acquisitions and asset sales. The credit facility provides that an event of
default will occur if there is a change in control. The payment of principal and interest under the credit facility is fully and unconditionally guaranteed, jointly and severally by the Company and
most of its existing wholly-owned subsidiaries. Substantially, all of the Company's assets are pledged to secure the credit facility. The Company exceeded the maximum senior debt/EBITDA ratio of 3.75
as of September 30, 2007. The Company also exceeded the maximum senior debt/EBITDA ratio of 3.75 and failed to meet the minimum fixed charge coverage ratio of 1.25 as of and for the rolling
twelve-month periods ended December 31, 2007 and March 31, 2008. In addition, the Company did not comply with certain administrative covenants including timely filing of its
Form 10-K for the year ended September 30, 2007 and its Forms 10-Q for the quarters ended

57

---



December 31,
2007 and March 31, 2008. The Company filed its Form 10-K on June 2, 2008 and its Form 10-Q for the quarter ended
December 31, 2008 on June 9, 2008.

On
February 13, 2008, April 10, 2008 and May 14, 2008, the Company and its lenders entered into forbearance agreements, whereby the lenders agreed not to exercise
their rights under the credit facility through May 15, 2008, subject to satisfaction of specified conditions. For the period January 28, 2008 through April 10, 2008, interest was
assessed at default rates of 11.4% with respect to the first lien term loan and 15.4% with respect to the second-lien term loan. Under the April 2008 forbearance agreements, the applicable
margin on the first and second lien term loans were permanently increased to 750 and 1,175 basis points, respectively, and the range of applicable margins on the revolving line of credit was increased
to 500 to 750 basis points effective April 10, 2008. During the forbearance periods, the Company had limited or no access to the line of credit. The Company also agreed to pay certain fees and
expenses to the lenders and their advisors as described below.

On
May 15, 2008, the Company and its lenders entered into an agreement to waive past covenant violations and amended the financial covenant provisions prospectively starting in
April 2008 to modify the required ratios and to increase the frequency of compliance reporting from quarterly to monthly for a specified period. Effective May 15, 2008, the maximum senior
debt/EBITDA ratios were increased to levels ranging from 3.90 to 7.15 for future monthly reporting periods from April 30, 2008 through June 30, 2009 and were increased to levels ranging
from 3.30 to 3.75 beginning with the September 30, 2009 quarterly reporting period through maturity of the term loan. The minimum fixed charge coverage ratios were reduced to levels ranging
from 0.475 to 0.925 for monthly reporting periods from April 30, 2008 through June 30, 2009 and were reduced to levels ranging from 0.85 to 0.90 beginning with the September 30,
2009 quarterly reporting periods through maturity of the term loan. The Company is also required to meet a new minimum EBITDA requirement for future monthly reporting periods from April 30,
2008 through June 30, 2009 and the remaining quarterly reporting periods through maturity of the term loan. In addition, the Company is required to, among other conditions, file its
Form 10-K for the year ended September 30, 2007 and the Forms 10-Q for the quarters ended December 31, 2007 and March 31, 2008 by
June 16, 2008. Failure to perform any
obligations under the wavier and the amended credit facility agreement constitutes additional events of default. As noted above, the Company filed its Form 10-K on June 2,
2008 and its Form 10-Q for the quarter ended December 31, 2007 on June 9, 2008. The Company has met all debt service requirements on a timely basis.

The
Company believes that it will be able to comply with the adjusted financial ratios through at least the next twelve months. As such, scheduled payments due after twelve months have
been classified as non-current at March 31, 2008. However, there can be no assurance that the Company will be able to meet all of the financial covenants and other conditions
required by the loan agreements for periods beyond the next twelve months. The lenders may not provide forbearance or grant waivers of future covenant violations and could require full repayment of
the loans, which would negatively impact the Company's liquidity, ability to operate and its ability to continue as a going concern.

In
connection with obtaining the waivers and amendments, the Company was required to pay $675,000 in fees to Bank of America, $2,274,000 in forbearance fees to the lenders, $400,000 in
legal and consulting fees to the lenders' advisors, and add 1% to the principal balance of the first and second lien debt of $1,415,000. In addition, the Company will incur an additional 4%
"payment-in-kind" interest expense on the second lien debt, which accrues and is added to the principal balance. The 4% may be reduced on a quarterly basis by 0.50% for each
0.25% reduction in the Company's consolidated leverage ratio. During the second quarter of 2008, the Company incurred $1,373,000 in fees to the lenders and their advisors related to the forbearance
agreements, of which $762,500 was recorded as interest expense and the balance was included in general and administrative expenses.

58

---



Item 4.    Submission of Matters to a Vote of Security Holders.

None.

Item 5.    Other Information.

None.

Item 6.    Exhibits.

The following documents are being filed as exhibits to this report:

|Exhibit No. |  | Title                                                                                                                                                                                                                               
|----------- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|3.1         |  | Amended and Restated Certificate of Incorporation of Prospect Medical Holdings, Inc.(1)                                                                                                                                             
|3.2         |  | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Prospect Medical Holdings, Inc.(1)                                                                                                                 
|3.3         |  | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Prospect Medical Holdings, Inc.(1)                                                                                                                 
|3.4         |  | Certificate of Designation of Series A Convertible Preferred Stock of Prospect Medical Holdings, Inc.(1)                                                                                                                            
|3.5         |  | Certificate of Elimination of Series A Convertible Preferred Stock of Prospect Medical Holdings, Inc.(2)                                                                                                                            
|3.6         |  | Certificate of Designation of Series B Preferred Stock of Prospect Medical Holdings, Inc.(3)                                                                                                                                        
|3.7         |  | Amended and Restated Bylaws of Prospect Medical Holdings, Inc.(1)                                                                                                                                                                   
|3.8         |  | First Amendment to Amended and Restated Bylaws of Prospect Medical Holdings, Inc.(1)                                                                                                                                                
|3.9         |  | Second Amendment to Amended and Restated Bylaws of Prospect Medical Holdings, Inc.(3)                                                                                                                                               
|4.1         |  | Specimen Common Stock Certificate(1)                                                                                                                                                                                                
|10.1        |  | First Amendment to Executive Employment Agreement dated as March 19, 2008 by and among Prospect Medical Holdings, Inc., Alta Hospitals System, LLC and Samuel S. Lee(4)                                                             
|10.2        |  | Form of First Lien Forbearance Agreement dated as of February 13, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto(5) 
|10.3        |  | Form of Second Lien Forbearance Agreement dated as of February 13, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto(5)
|10.4        |  | Form of First Amendment to Forbearance Agreement dated as of March 31, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., and Bank of America, N.A., as Administrative Agent(5)                       
|10.5        |  | Form of Consent Under Second Lien Forbearance Agreement dated as of March 31, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., and Bank of America, N.A., as Administrative Agent(5)                
|31.1        |  | Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended.                                                                                               

59

---



|31.2 |  | Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended.             
|---- |  | --------------------------------------------------------------------------------------------------------------------------------------------------
|32.1 |  | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
|32.2 |  | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

---

60

---





SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.

|              |  | PROSPECT MEDICAL HOLDINGS, INC.(Registrant)                                        
|------------- |  | -----------------------------------------------------------------------------------
|              |  |                                                                                    
|              |  |                                                                                    
|June 16, 2008 |  | /s/SAMUEL S. LEESamuel S. Lee
Chief Executive Officer
(Principal Executive Officer)
|              |  |                                                                                    
|June 16, 2008 |  | /s/MIKE HEATHERMike Heather
Chief Financial Officer
(Principal Financial Officer)  

61

---





Exhibit Index

|Exhibit No. |  | Title                                                                                                                                                                                                                               
|----------- |  | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
|3.1         |  | Amended and Restated Certificate of Incorporation of Prospect Medical Holdings, Inc.(1)                                                                                                                                             
|3.2         |  | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Prospect Medical Holdings, Inc.(1)                                                                                                                 
|3.3         |  | Certificate of Amendment of Amended and Restated Certificate of Incorporation of Prospect Medical Holdings, Inc.(1)                                                                                                                 
|3.4         |  | Certificate of Designation of Series A Convertible Preferred Stock of Prospect Medical Holdings, Inc.(1)                                                                                                                            
|3.5         |  | Certificate of Elimination of Series A Convertible Preferred Stock of Prospect Medical Holdings, Inc.(2)                                                                                                                            
|3.6         |  | Certificate of Designation of Series B Preferred Stock of Prospect Medical Holdings, Inc.(3)                                                                                                                                        
|3.7         |  | Amended and Restated Bylaws of Prospect Medical Holdings, Inc.(1)                                                                                                                                                                   
|3.8         |  | First Amendment to Amended and Restated Bylaws of Prospect Medical Holdings, Inc.(1)                                                                                                                                                
|3.9         |  | Second Amendment to Amended and Restated Bylaws of Prospect Medical Holdings, Inc.(3)                                                                                                                                               
|4.1         |  | Specimen Common Stock Certificate(1)                                                                                                                                                                                                
|10.1        |  | First Amendment to Executive Employment Agreement dated as March 19, 2008 by and among Prospect Medical Holdings, Inc., Alta Hospitals System, LLC and Samuel S. Lee(4)                                                             
|10.2        |  | Form of First Lien Forbearance Agreement dated as of February 13, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto(5) 
|10.3        |  | Form of Second Lien Forbearance Agreement dated as of February 13, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., Bank of America, N.A., as Administrative Agent, and the lenders party thereto(5)
|10.4        |  | Form of First Amendment to Forbearance Agreement dated as of March 31, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., and Bank of America, N.A., as Administrative Agent(5)                       
|10.5        |  | Form of Consent Under Second Lien Forbearance Agreement dated as of March 31, 2008 by and among Prospect Medical Holdings, Inc., Prospect Medical Group, Inc., and Bank of America, N.A., as Administrative Agent(5)                
|31.1        |  | Certification of Chief Executive Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended.                                                                                               
|31.2        |  | Certification of Chief Financial Officer pursuant to Rules 13a-14(a)/15d-14(a) under the Securities Exchange Act of 1934, as amended.                                                                                               
|32.1        |  | Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                  
|32.2        |  | Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.                                                                                  

---

62

---



QuickLinks